{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 17162, "items": [{"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T22:35:06Z", "timestamp": 1575498906726}, "reference-count": 10, "publisher": "Wiley", "issue": "12", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 420, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Journal of Clinical Pharmacology"], "published-print": {"date-parts": [[2014, 12]]}, "DOI": "10.1002/jcph.355", "type": "journal-article", "created": {"date-parts": [[2014, 7, 2]], "date-time": "2014-07-02T17:55:25Z", "timestamp": 1404323725000}, "page": "1347-1353", "source": "Crossref", "is-referenced-by-count": 9, "title": ["First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting \u03922-agonist"], "prefix": "10.1002", "volume": "54", "author": [{"given": "Wolfgang", "family": "Timmer", "sequence": "first", "affiliation": [{"name": "Clinical Research Services Mannheim GmbH; Germany"}]}, {"given": "Eric", "family": "Massana", "sequence": "additional", "affiliation": [{"name": "R&D Centre; Almirall; Barcelona Spain"}]}, {"given": "Eulalia", "family": "Jimenez", "sequence": "additional", "affiliation": [{"name": "R&D Centre; Almirall; Barcelona Spain"}]}, {"given": "Beatriz", "family": "Seoane", "sequence": "additional", "affiliation": [{"name": "R&D Centre; Almirall; Barcelona Spain"}]}, {"given": "Gonzalo", "family": "de Miquel", "sequence": "additional", "affiliation": [{"name": "R&D Centre; Almirall; Barcelona Spain"}]}, {"given": "Sandrine", "family": "Ruiz", "sequence": "additional", "affiliation": [{"name": "R&D Centre; Almirall; Barcelona Spain"}]}], "member": "311", "published-online": {"date-parts": [[2014, 7, 8]]}, "reference": [{"key": "10.1002/jcph.355-BIB0001|jcph355-cit-0001", "unstructured": "www.ginasthma.org"}, {"key": "10.1002/jcph.355-BIB0002|jcph355-cit-0002", "unstructured": "http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf"}, {"key": "10.1002/jcph.355-BIB0003|jcph355-cit-0003", "unstructured": "http://www.who.int/whr/2000/en/"}, {"key": "10.1002/jcph.355-BIB0004|jcph355-cit-0004", "unstructured": "http://www.brit-thoracic.org.uk/guidelines/asthma-guidelines.aspx"}, {"issue": "2", "key": "10.1002/jcph.355-BIB0005|jcph355-cit-0005", "doi-asserted-by": "crossref", "first-page": "497", "DOI": "10.1124/jpet.112.193284", "article-title": "Pharmacological characterization of abediterol, a novel inhaled \u03b2(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models", "volume": "342", "author": "Aparici", "year": "2012", "journal-title": "J Pharmacol Exp Ther"}, {"key": "10.1002/jcph.355-BIB0006|jcph355-cit-0006", "unstructured": ""}, {"key": "10.1002/jcph.355-BIB0007|jcph355-cit-0007", "unstructured": "Beier J Fuhr R Massana \u00c8 2"}, {"key": "10.1002/jcph.355-BIB0008|jcph355-cit-0008", "unstructured": "Singh D Pujol H Ribera A"}, {"key": "10.1002/jcph.355-BIB0009|jcph355-cit-0009", "author": "AACR Clinical Practice Guidelines", "volume": "46", "first-page": "506", "year": "2001", "journal-title": "Respir Care"}, {"issue": "1", "key": "10.1002/jcph.355-BIB0010|jcph355-cit-0010", "doi-asserted-by": "crossref", "first-page": "55", "DOI": "10.1016/j.pupt.2010.10.006", "article-title": "The duration of bronchodilation of salmeterol and salbutamol as measured by specific airway conductance in healthy subjects", "volume": "24", "author": "Pullerits", "year": "2011", "journal-title": "Pulm Pharmacol Ther"}], "container-title": ["The Journal of Clinical Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjcph.355", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 22]], "date-time": "2017-06-22T16:04:25Z", "timestamp": 1498147465000}, "score": 84.09288, "issued": {"date-parts": [[2014, 7, 8]]}, "references-count": 10, "journal-issue": {"published-print": {"date-parts": [[2014, 12]]}, "issue": "12"}, "URL": "http://dx.doi.org/10.1002/jcph.355", "relation": {"cites": []}, "ISSN": ["0091-2700"], "issn-type": [{"value": "0091-2700", "type": "print"}], "subject": ["Pharmacology (medical)", "Pharmacology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T18:48:12Z", "timestamp": 1575226092716}, "reference-count": 0, "publisher": "American Thoracic Society", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2010, 5]]}, "DOI": "10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5663", "type": "proceedings-article", "created": {"date-parts": [[2013, 5, 23]], "date-time": "2013-05-23T12:35:38Z", "timestamp": 1369312538000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Single Doses Of LAS100977, A Novel Long Acting \u00b22-agonist, Show High Activity And Long Duration In Healthy Subjects"], "prefix": "10.1164", "author": [{"given": "Wolfgang", "family": "Timmer", "sequence": "first", "affiliation": []}, {"given": "\u00c8ric", "family": "Massana", "sequence": "additional", "affiliation": []}, {"given": "Eulalia", "family": "Jim\u00e9nez", "sequence": "additional", "affiliation": []}, {"given": "Beatriz", "family": "Seoane", "sequence": "additional", "affiliation": []}, {"given": "Gonzalo", "family": "de Miquel", "sequence": "additional", "affiliation": []}, {"given": "Sandrine", "family": "Ruiz", "sequence": "additional", "affiliation": []}], "member": "19", "event": {"name": "American Thoracic Society 2010 International Conference, May 14-19, 2010 \u2022 New Orleans"}, "container-title": ["D34. NOVEL THERAPEUTIC OPTIONS IN AIRWAYS DISEASE"], "deposited": {"date-parts": [[2013, 5, 23]], "date-time": "2013-05-23T12:35:42Z", "timestamp": 1369312542000}, "score": 45.053734, "issued": {"date-parts": [[2010, 5]]}, "references-count": 0, "alternative-id": ["10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A5663", "10.1164/ajrccm-conference.2010.D034"], "URL": "http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5663"}, {"institution": {"name": "ISRCTN", "place": ["London, UK"], "acronym": ["-"]}, "indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T07:07:21Z", "timestamp": 1575184041570}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "content-domain": {"domain": ["www.isrctn.com"], "crossmark-restriction": true}, "DOI": "10.1186/isrctn64029954", "type": "dataset", "created": {"date-parts": [[2013, 2, 19]], "date-time": "2013-02-19T11:32:41Z", "timestamp": 1361273561000}, "update-policy": "http://dx.doi.org/10.1186/isrctn_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Multiple-dose tolerability and effect of food"], "prefix": "10.1186", "author": [{"given": "Wolfgang", "family": "Timmer", "sequence": "first", "affiliation": []}], "member": "297", "content-created": {"date-parts": [[2013, 2, 18]]}, "container-title": ["http://isrctn.org/>"], "deposited": {"date-parts": [[2015, 6, 12]], "date-time": "2015-06-12T14:10:13Z", "timestamp": 1434118213000}, "score": 33.657417, "issued": {"date-parts": [[2013, 2, 18]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1186/isrctn64029954"}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T06:41:37Z", "timestamp": 1574750497084}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "7", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 7, 1]], "date-time": "2015-07-01T00:00:00Z", "timestamp": 1435708800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Alzheimer's & Dementia"], "published-print": {"date-parts": [[2015, 7]]}, "DOI": "10.1016/j.jalz.2015.06.496", "type": "journal-article", "created": {"date-parts": [[2015, 12, 15]], "date-time": "2015-12-15T10:47:03Z", "timestamp": 1450176423000}, "page": "P468-P469", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-rising doses of bi409306 film-coated tablets given orally once- or twice-daily for 14 days in young and elderly healthy volunteers"], "prefix": "10.1016", "volume": "11", "author": [{"given": "Viktoria", "family": "Moschetti", "sequence": "first", "affiliation": []}, {"given": "Katja", "family": "Boland", "sequence": "additional", "affiliation": []}, {"given": "Anja", "family": "Hoch", "sequence": "additional", "affiliation": []}, {"given": "Wolfgang", "family": "Timmer", "sequence": "additional", "affiliation": []}, {"given": "Heike", "family": "Zimdahl-Gelling", "sequence": "additional", "affiliation": []}, {"given": "Andreas", "family": "Borta", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Sand", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Alzheimer's & Dementia"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1552526015007335?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1552526015007335?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 17]], "date-time": "2018-09-17T01:22:42Z", "timestamp": 1537147362000}, "score": 33.63658, "issued": {"date-parts": [[2015, 7]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2015, 7]]}, "issue": "7"}, "alternative-id": ["S1552526015007335"], "URL": "http://dx.doi.org/10.1016/j.jalz.2015.06.496", "ISSN": ["1552-5260"], "issn-type": [{"value": "1552-5260", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T05:03:40Z", "timestamp": 1574226220372}, "reference-count": 32, "publisher": "Wiley", "issue": "9", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3287, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2006, 9]]}, "DOI": "10.1177/0091270006292127", "type": "journal-article", "created": {"date-parts": [[2006, 8, 18]], "date-time": "2006-08-18T17:53:12Z", "timestamp": 1155923592000}, "page": "981-990", "source": "Crossref", "is-referenced-by-count": 118, "title": ["Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban-an Oral, Direct Factor Xa Inhibitor-Are Not Affected by Aspirin"], "prefix": "10.1002", "volume": "46", "author": [{"given": "Dagmar", "family": "Kubitza", "sequence": "first", "affiliation": []}, {"given": "Michael", "family": "Becka", "sequence": "additional", "affiliation": []}, {"given": "Wolfgang", "family": "Mueck", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Zuehlsdorf", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2013, 3, 8]]}, "reference": [{"key": "10.1177/0091270006292127-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "338S", "DOI": "10.1378/chest.126.3_suppl.338S", "article-title": "Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy", "volume": "126", "author": "Geerts", "year": "2004", "journal-title": "Chest"}, {"key": "10.1177/0091270006292127-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "429S", "DOI": "10.1378/chest.126.3_suppl.429S", "article-title": "Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy", "volume": "126", "author": "Singer", "year": "2004", "journal-title": "Chest"}, {"key": "10.1177/0091270006292127-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "513S", "DOI": "10.1378/chest.126.3_suppl.513S", "article-title": "Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy", "volume": "126", "author": "Harrington", "year": "2004", "journal-title": "Chest"}, {"key": "10.1177/0091270006292127-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.2165/00003495-200464001-00002", "article-title": "Current options in the prevention of thromboembolic disease", "volume": "64", "author": "Ansell", "year": "2004", "journal-title": "Drugs"}, {"key": "10.1177/0091270006292127-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "189", "DOI": "10.1007/s00018-002-8415-9", "article-title": "Factor Xa: a promising target for drug development", "volume": "59", "author": "Kaiser", "year": "2002", "journal-title": "Cell Mol Life Sci"}, {"key": "10.1177/0091270006292127-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "514", "DOI": "10.1111/j.1538-7836.2005.01166.x", "article-title": "In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor", "volume": "3", "author": "Perzborn", "year": "2005", "journal-title": "J Thromb Haemost"}, {"key": "10.1177/0091270006292127-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "412", "DOI": "10.1016/j.clpt.2005.06.011", "article-title": "Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor", "volume": "78", "author": "Kubitza", "year": "2005", "journal-title": "Clin Pharmacol Ther"}, {"key": "10.1177/0091270006292127-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "873", "DOI": "10.1007/s00228-005-0043-5", "article-title": "Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects", "volume": "61", "author": "Kubitza", "year": "2005", "journal-title": "Eur J Clin Pharmacol"}, {"key": "10.1177/0091270006292127-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "2479", "DOI": "10.1111/j.1538-7836.2005.01602.x", "article-title": "BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study", "volume": "3", "author": "Turpie", "year": "2005", "journal-title": "J Thromb Haemost"}, {"key": "10.1177/0091270006292127-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "121", "DOI": "10.1111/j.1538-7836.2005.01657.x", "article-title": "Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement", "volume": "4", "author": "Eriksson", "year": "2006", "journal-title": "J Thromb Haemost"}, {"key": "10.1177/0091270006292127-BIB11|cit11", "author": "Eriksson", "first-page": "106", "year": "2005", "article-title": "Prevention of venous thromboembolism after total hip replacement with once-daily BAY 59-7939-an oral, direct Factor Xa inhibitor", "journal-title": "Blood"}, {"key": "10.1177/0091270006292127-BIB12|cit12", "first-page": "531", "article-title": "The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines", "volume": "51", "author": "Hostetter", "year": "2003", "journal-title": "Minerva Cardioangiol"}, {"key": "10.1177/0091270006292127-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.1136/bmj.324.7329.71", "article-title": "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients", "volume": "324", "author": "Antithrombotic Trialists Collaboration.", "year": "2002", "journal-title": "BMJ."}, {"key": "10.1177/0091270006292127-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "234S", "DOI": "10.1378/chest.126.3_suppl.234S", "article-title": "Plateletactive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy", "volume": "126", "author": "Patrono", "year": "2004", "journal-title": "Chest"}, {"key": "10.1177/0091270006292127-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "483S", "DOI": "10.1378/chest.126.3_suppl.483S", "article-title": "Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy", "volume": "126", "author": "Albers", "year": "2004", "journal-title": "Chest"}, {"key": "10.1177/0091270006292127-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "1809", "DOI": "10.1053/euhj.2002.3385", "article-title": "Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation", "volume": "23", "author": "Bertrand", "year": "2002", "journal-title": "Eur Heart J"}, {"key": "10.1177/0091270006292127-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "178", "DOI": "10.1113/jphysiol.1963.sp007185", "article-title": "The aggregation of blood platelets", "volume": "168", "author": "Born", "year": "1963", "journal-title": "J Physiol"}, {"key": "10.1177/0091270006292127-BIB18|cit18", "first-page": "210", "article-title": "Measurement of the bleeding time", "volume": "52", "author": "Mielke", "year": "1984", "journal-title": "Thromb Haemost"}, {"key": "10.1177/0091270006292127-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "891", "DOI": "10.1080/00498250500250493", "article-title": "Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs", "volume": "35", "author": "Weinz", "year": "2005", "journal-title": "Xenobiotica"}, {"key": "10.1177/0091270006292127-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "461", "DOI": "10.1016/S0049-3848(00)00297-8", "article-title": "Inhibitory activity of aspirin on von Willebrand factor-induced platelet aggregation", "volume": "99", "author": "Homoncik", "year": "2000", "journal-title": "Thromb Res"}, {"issue": "suppl 2", "key": "10.1177/0091270006292127-BIB21|cit21", "first-page": "113", "article-title": "Preliminary data from a field trial of the PFA-100 system", "volume": "21", "author": "Mammen", "year": "1995", "journal-title": "Semin Thromb Hemost"}, {"issue": "suppl 2", "key": "10.1177/0091270006292127-BIB22|cit22", "article-title": "Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct Factor Xa inhibitor", "volume": "33", "author": "Perzborn", "year": "2004", "journal-title": "Pathophysiol Haemost Thromb"}, {"issue": "suppl 1", "key": "10.1177/0091270006292127-BIB23|cit23", "article-title": "Interaction of BAY 59-7939-a novel, oral, direct Factor Xa inhibitor-with antiplatelet agents: monitoring and therapeutic applications", "volume": "3", "author": "Hoppensteadt", "year": "2005", "journal-title": "J Thromb Haemost"}, {"key": "10.1177/0091270006292127-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "820", "DOI": "10.1097/00000658-200206000-00009", "article-title": "Aspirin and postoperative bleeding after coronary artery bypass grafting", "volume": "235", "author": "Ferraris", "year": "2002", "journal-title": "Ann Surg"}, {"key": "10.1177/0091270006292127-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1055/s-2007-1002658", "article-title": "A critical reappraisal of the bleeding time", "volume": "16", "author": "Rodgers", "year": "1990", "journal-title": "Semin Thromb Hemost"}, {"key": "10.1177/0091270006292127-BIB26|cit26", "author": "International Technidyne Corporation.", "year": "2000", "volume-title": "Surgicutt bleeding time determination device [manufacturer's instructions]"}, {"key": "10.1177/0091270006292127-BIB27|cit27", "first-page": "2547", "article-title": "The bleeding time does not predict surgical bleeding", "volume": "77", "author": "Lind", "year": "1991", "journal-title": "Blood"}, {"key": "10.1177/0091270006292127-BIB28|cit28", "unstructured": "US Food and Drug Administration Center for Drug Evaluation and Research. Bioavailability and bioequivalence studies for orally administered drug products-general considerations 2002 http://www.fda.gov/cder/guidance/3615fnl.htm"}, {"issue": "suppl 2", "key": "10.1177/0091270006292127-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.2165/00003088-200241002-00005", "article-title": "Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers", "volume": "41", "author": "Ollier", "year": "2002", "journal-title": "Clin Pharmacokinet"}, {"key": "10.1177/0091270006292127-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "283", "DOI": "10.1007/s00228-003-0619-x", "article-title": "Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid", "volume": "59", "author": "Fager", "year": "2003", "journal-title": "Eur J Clin Pharmacol"}, {"key": "10.1177/0091270006292127-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "241", "DOI": "10.7326/0003-4819-143-4-200508160-00005", "article-title": "Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit", "volume": "143", "author": "Rothberg", "year": "2005", "journal-title": "Ann Intern Med"}, {"key": "10.1177/0091270006292127-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "555", "DOI": "10.1177/0091270005274550", "article-title": "Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement", "volume": "45", "author": "Stangier", "year": "2005", "journal-title": "J Clin Pharmacol"}], "container-title": ["The Journal of Clinical Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1177%2F0091270006292127", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 17]], "date-time": "2017-06-17T08:36:33Z", "timestamp": 1497688593000}, "score": 33.454556, "issued": {"date-parts": [[2006, 9]]}, "references-count": 32, "journal-issue": {"published-print": {"date-parts": [[2006, 9]]}, "issue": "9"}, "URL": "http://dx.doi.org/10.1177/0091270006292127", "relation": {"cites": []}, "ISSN": ["0091-2700"], "issn-type": [{"value": "0091-2700", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T02:38:39Z", "timestamp": 1575513519378}, "reference-count": 36, "publisher": "Springer Science and Business Media LLC", "license": [{"URL": "https://creativecommons.org/licenses/by-nc/4.0", "start": {"date-parts": [[2019, 9, 16]], "date-time": "2019-09-16T00:00:00Z", "timestamp": 1568592000000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"DOI": "10.13039/100009945", "name": "Merck KGaA", "doi-asserted-by": "crossref", "award": []}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Eur J Drug Metab Pharmacokinet"], "DOI": "10.1007/s13318-019-00575-7", "type": "journal-article", "created": {"date-parts": [[2019, 9, 16]], "date-time": "2019-09-16T14:03:05Z", "timestamp": 1568642585000}, "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects"], "prefix": "10.1007", "author": [{"given": "Daniela", "family": "Willen", "sequence": "first", "affiliation": []}, {"given": "Wolfgang", "family": "Uhl", "sequence": "additional", "affiliation": []}, {"given": "Peter", "family": "Wolna", "sequence": "additional", "affiliation": []}, {"given": "Orestis", "family": "Papasouliotis", "sequence": "additional", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0001-6860-2794", "authenticated-orcid": false, "given": "\u00d6zkan", "family": "Yalkinoglu", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2019, 9, 16]]}, "reference": [{"issue": "1", "key": "575_CR1", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1080/08830185.2016.1276903", "volume": "36", "author": "E Samy", "year": "2017", "unstructured": "Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3\u201319.", "journal-title": "Int Rev Immunol"}, {"issue": "2", "key": "575_CR2", "doi-asserted-by": "publisher", "first-page": "R48", "DOI": "10.1186/ar2959", "volume": "12", "author": "SR Dillon", "year": "2010", "unstructured": "Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010;12(2):R48.", "journal-title": "Arthritis Res Ther"}, {"issue": "5537", "key": "575_CR3", "doi-asserted-by": "publisher", "first-page": "2111", "DOI": "10.1126/science.1061964", "volume": "293", "author": "B Schiemann", "year": "2001", "unstructured": "Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293(5537):2111\u20134.", "journal-title": "Science"}, {"issue": "5", "key": "575_CR4", "doi-asserted-by": "publisher", "first-page": "2755", "DOI": "10.1182/blood-2007-09-110858", "volume": "111", "author": "E Belnoue", "year": "2008", "unstructured": "Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008;111(5):2755\u201364.", "journal-title": "Blood"}, {"issue": "7", "key": "575_CR5", "doi-asserted-by": "publisher", "first-page": "1838", "DOI": "10.1182/blood-2011-01-332940", "volume": "118", "author": "T Matthes", "year": "2011", "unstructured": "Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, Passweg J, et al. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood. 2011;118(7):1838\u201344.", "journal-title": "Blood"}, {"issue": "6", "key": "575_CR6", "doi-asserted-by": "publisher", "first-page": "1075", "DOI": "10.1002/eji.201746934", "volume": "47", "author": "P Haselmayer", "year": "2017", "unstructured": "Haselmayer P, Vigolo M, Nys J, Schneider P, Hess H. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells. Eur J Immunol. 2017;47(6):1075\u201385.", "journal-title": "Eur J Immunol"}, {"issue": "4", "key": "575_CR7", "doi-asserted-by": "publisher", "first-page": "713", "DOI": "10.1002/eji.201646630", "volume": "47", "author": "NL Tran", "year": "2017", "unstructured": "Tran NL, Schneider P, Santiago-Raber ML. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus. Eur J Immunol. 2017;47(4):713\u201323.", "journal-title": "Eur J Immunol"}, {"issue": "2", "key": "575_CR8", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1016/S1074-7613(01)00183-2", "volume": "15", "author": "JA Gross", "year": "2001", "unstructured": "Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15(2):289\u2013302.", "journal-title": "Immunity"}, {"issue": "6", "key": "575_CR9", "doi-asserted-by": "publisher", "first-page": "997", "DOI": "10.1136/ard.2008.090928", "volume": "68", "author": "J Morel", "year": "2009", "unstructured": "Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(6):997\u20131002.", "journal-title": "Ann Rheum Dis"}, {"issue": "4", "key": "575_CR10", "doi-asserted-by": "publisher", "first-page": "683", "DOI": "10.5301/jn.5000218", "volume": "26", "author": "G Xin", "year": "2013", "unstructured": "Xin G, Shi W, Xu LX, Su Y, Yan LJ, Li KS. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol. 2013;26(4):683\u201390.", "journal-title": "J Nephrol"}, {"issue": "6", "key": "575_CR11", "doi-asserted-by": "publisher", "first-page": "1313", "DOI": "10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S", "volume": "44", "author": "GS Cheema", "year": "2001", "unstructured": "Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313\u20139.", "journal-title": "Arthritis Rheum"}, {"issue": "3", "key": "575_CR12", "doi-asserted-by": "publisher", "first-page": "189", "DOI": "10.1007/s10875-005-4091-5", "volume": "25", "author": "MV Jonsson", "year": "2005", "unstructured": "Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren\u2019s syndrome. J Clin Immunol. 2005;25(3):189\u2013201.", "journal-title": "J Clin Immunol"}, {"issue": "11", "key": "575_CR13", "doi-asserted-by": "publisher", "first-page": "2006", "DOI": "10.1136/annrheumdis-2013-205067", "volume": "74", "author": "D Isenberg", "year": "2015", "unstructured": "Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006\u201315.", "journal-title": "Ann Rheum Dis"}, {"issue": "2", "key": "575_CR14", "doi-asserted-by": "publisher", "first-page": "266", "DOI": "10.1002/art.40360", "volume": "70", "author": "JT Merrill", "year": "2018", "unstructured": "Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70(2):266\u201376.", "journal-title": "Arthritis Rheumatol"}, {"issue": "7", "key": "575_CR15", "doi-asserted-by": "publisher", "first-page": "647", "DOI": "10.1007/s00228-007-0311-7", "volume": "63", "author": "A Munafo", "year": "2007", "unstructured": "Munafo A, Priestley A, Nestorov I, Visich J, Rogge M. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol. 2007;63(7):647\u201356.", "journal-title": "Eur J Clin Pharmacol"}, {"issue": "12", "key": "575_CR16", "doi-asserted-by": "publisher", "first-page": "4142", "DOI": "10.1002/art.23047", "volume": "56", "author": "M Dall\u2019Era", "year": "2007", "unstructured": "Dall\u2019Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56(12):4142\u201350.", "journal-title": "Arthritis Rheum"}, {"issue": "6", "key": "575_CR17", "doi-asserted-by": "publisher", "first-page": "547", "DOI": "10.1177/0961203309102803", "volume": "18", "author": "C Pena-Rossi", "year": "2009", "unstructured": "Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18(6):547\u201355.", "journal-title": "Lupus"}, {"issue": "1", "key": "575_CR18", "doi-asserted-by": "publisher", "first-page": "524", "DOI": "10.1002/jps.21839", "volume": "99", "author": "I Nestorov", "year": "2010", "unstructured": "Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci. 2010;99(1):524\u201338.", "journal-title": "J Pharm Sci"}, {"issue": "4", "key": "575_CR19", "doi-asserted-by": "publisher", "first-page": "1105", "DOI": "10.1158/1078-0432.CCR-07-4435", "volume": "14", "author": "SM Ansell", "year": "2008", "unstructured": "Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin\u2019s lymphoma. Clin Cancer Res. 2008;14(4):1105\u201310.", "journal-title": "Clin Cancer Res"}, {"issue": "4", "key": "575_CR20", "doi-asserted-by": "publisher", "first-page": "406", "DOI": "10.1177/0091270008315312", "volume": "48", "author": "I Nestorov", "year": "2008", "unstructured": "Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol. 2008;48(4):406\u201317.", "journal-title": "J Clin Pharmacol"}, {"issue": "7", "key": "575_CR21", "doi-asserted-by": "publisher", "first-page": "1051", "DOI": "10.1038/sj.bjc.6605241", "volume": "101", "author": "JF Rossi", "year": "2009", "unstructured": "Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouille V, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom\u2019s macroglobulinemia: a phase I study. Br J Cancer. 2009;101(7):1051\u20138.", "journal-title": "Br J Cancer"}, {"issue": "3", "key": "575_CR22", "first-page": "9", "volume": "22", "author": "K Berelowitz", "year": "2011", "unstructured": "Berelowitz K, Taubel J. Early phase Japanese bridging studies\u2014global significance and CRO selection criteria. CRfocus. 2011;22(3):9\u201313.", "journal-title": "CRfocus"}, {"key": "575_CR23", "unstructured": "Bhupathi C, Vajjha VH. Sample size recommendation for a bioequivalent study. Statistica. 2017;77:65\u201371."}, {"key": "575_CR24", "unstructured": "European Medicines Agency. VICH GL 52: bioequivalence: blood level bioequivalence study. London: European Medicines Agency; 2015."}, {"issue": "1", "key": "575_CR25", "doi-asserted-by": "publisher", "first-page": "38", "DOI": "10.1002/pst.326", "volume": "8", "author": "J Hummel", "year": "2009", "unstructured": "Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8(1):38\u201349.", "journal-title": "Pharm Stat"}, {"issue": "suppl 2", "key": "575_CR26", "doi-asserted-by": "publisher", "first-page": "1077", "DOI": "10.1136/annrheumdis-2015-eular.3504", "volume": "74", "author": "O Papasouliotis", "year": "2015", "unstructured": "Papasouliotis O, Yalkinoglu \u00d6, Golob M, Willen D, Girard P. Population pharmacokinetics of atacicept in systemic lupus erythematosus (SLE). Ann Rheum Dis. 2015;74(suppl 2):1077 (Abstract).", "journal-title": "Ann Rheum Dis"}, {"issue": "5", "key": "575_CR27", "doi-asserted-by": "publisher", "first-page": "573", "DOI": "10.1007/s10928-008-9102-8", "volume": "35", "author": "L Gibiansky", "year": "2008", "unstructured": "Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35(5):573\u201391.", "journal-title": "J Pharmacokinet Pharmacodyn"}, {"key": "575_CR28", "unstructured": "Statistics Bureau Japan. Ministry of Internal Affairs and Communications website: weight by age and sex (1900\u20132004). 2004. Available from: \n                  http://www.stat.go.jp/english/data/chouki/24.htm\n                  \n                . Accessed 20 December 2016."}, {"key": "575_CR29", "author": "D Ruston", "year": "2004", "unstructured": "Ruston D, Hoare J, Henderson L, Gregory J, Bates CJ, Prentice A, et al. The national diet and nutrition survey: adults aged 19 to 64 years, vol. 4. Nutritional status (anthropometry and blood analytes), blood pressure and physical activity; 2004. London: The Stationery Office.", "series-title": "Nutritional status (anthropometry and blood analytes), blood pressure and physical activity", "volume-title": "The national diet and nutrition survey: adults aged 19 to 64 years"}, {"issue": "4", "key": "575_CR30", "doi-asserted-by": "publisher", "first-page": "803", "DOI": "10.1016/j.iac.2008.06.006", "volume": "28", "author": "FA Bonilla", "year": "2008", "unstructured": "Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28(4):803\u201319.", "journal-title": "Immunol Allergy Clin North Am"}, {"issue": "7", "key": "575_CR31", "doi-asserted-by": "publisher", "first-page": "1782", "DOI": "10.1002/art.30372", "volume": "63", "author": "RF Vollenhoven van", "year": "2011", "unstructured": "van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1782\u201392.", "journal-title": "Arthritis Rheum"}, {"issue": "11", "key": "575_CR32", "doi-asserted-by": "publisher", "first-page": "2828", "DOI": "10.1002/art.39262", "volume": "67", "author": "RF Vollenhoven van", "year": "2015", "unstructured": "van Vollenhoven RF, Wax S, Li Y, Tak PP. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial. Arthritis Rheumatol. 2015;67(11):2828\u201336.", "journal-title": "Arthritis Rheumatol"}, {"issue": "suppl", "key": "575_CR33", "first-page": "10", "volume": "67", "author": "C Dascalu", "year": "2015", "unstructured": "Dascalu C, Davidson A, Mackay MC, Furie R, Huang W, Aranow C. The effect of belimumab on peripheral blood cells in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(suppl):10.", "journal-title": "Arthritis Rheumatol"}, {"issue": "7", "key": "575_CR34", "doi-asserted-by": "publisher", "first-page": "2328", "DOI": "10.1002/art.34400", "volume": "64", "author": "W Stohl", "year": "2012", "unstructured": "Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328\u201337.", "journal-title": "Arthritis Rheum"}, {"issue": "1", "key": "575_CR35", "doi-asserted-by": "publisher", "first-page": "201", "DOI": "10.1002/art.27189", "volume": "62", "author": "AM Jacobi", "year": "2010", "unstructured": "Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201\u201310.", "journal-title": "Arthritis Rheum"}, {"issue": "1", "key": "575_CR36", "doi-asserted-by": "publisher", "first-page": "61", "DOI": "10.1002/art.23178", "volume": "58", "author": "PP Tak", "year": "2008", "unstructured": "Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61\u201372.", "journal-title": "Arthritis Rheum"}], "container-title": ["European Journal of Drug Metabolism and Pharmacokinetics"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s13318-019-00575-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s13318-019-00575-7/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s13318-019-00575-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 26]], "date-time": "2019-10-26T00:27:56Z", "timestamp": 1572049676000}, "score": 30.303835, "issued": {"date-parts": [[2019, 9, 16]]}, "references-count": 36, "alternative-id": ["575"], "URL": "http://dx.doi.org/10.1007/s13318-019-00575-7", "relation": {"cites": []}, "ISSN": ["0378-7966", "2107-0180"], "issn-type": [{"value": "0378-7966", "type": "print"}, {"value": "2107-0180", "type": "electronic"}], "subject": ["Pharmacology (medical)", "Pharmacology"], "assertion": [{"value": "16 September 2019", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Compliance with Ethical Standards"}}, {"value": "This study was sponsored by Merck KGaA, Darmstadt, Germany.", "order": 2, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Funding"}}, {"value": "Daniela Willen, Wolfgang Uhl and Peter Wolna were employees of Merck KGaA, Darmstadt, Germany at the time of this study. \u00d6zkan Yalkinoglu is an employee of Merck KGaA, Darmstadt, Germany. Orestis Papasouliotis is an employee of Merck Institute for Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.", "order": 3, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Conflicts of interest"}}, {"value": "The protocol was approved by the Office for Research Ethics Committees Northern Ireland and the study was conducted at the Quintiles Drug Research Unit, Guy\u2019s Hospital, in the UK (EudraCT ID: 2013-002703-34; study: EMR 700461-022), in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice, the Declaration of Helsinki, the European Union Clinical Trial Directive, and all applicable local regulatory requirements.", "order": 4, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Ethical approval"}}, {"value": "Atacicept is under clinical investigation and has not yet been approved in any sought-after indication by any health authority worldwide. Therefore, there is no plan for data sharing at this point in time. Please note that for all new products or new indications approved in both the European Union and the United States after January 1, 2014, Merck will share patient level, study level data after de-identification, as well as redacted study protocols and clinical study reports from clinical trials in patients. These data will be shared with qualified scientific and medical researchers, upon researcher\u2019s request, as necessary for conducting legitimate research. Such requests must be submitted in writing to the company\u2019s data sharing portal and will be internally reviewed regarding criteria for researcher qualifications and legitimacy of the research purpose (ExternalRef removed).", "order": 5, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Data sharing statement"}}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T18:49:32Z", "timestamp": 1575226172221}, "reference-count": 0, "publisher": "American Thoracic Society", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011, 5]]}, "DOI": "10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3730", "type": "proceedings-article", "created": {"date-parts": [[2013, 5, 23]], "date-time": "2013-05-23T12:49:27Z", "timestamp": 1369313367000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Safety, Tolerability And Pharmacokinetics Of Ciprofloxacin Dry Powder For Inhalation In Patients With Mild To Moderate Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial"], "prefix": "10.1164", "author": [{"given": "Heino", "family": "Stass", "sequence": "first", "affiliation": []}, {"given": "Johannes", "family": "Nagelschmitz", "sequence": "additional", "affiliation": []}, {"given": "Boris", "family": "Weimann", "sequence": "additional", "affiliation": []}, {"given": "Wolfgang", "family": "Timmer", "sequence": "additional", "affiliation": []}], "member": "19", "event": {"name": "American Thoracic Society 2011 International Conference, May 13-18, 2011 \u2022 Denver Colorado"}, "container-title": ["B93. COPD EXACERBATIONS: IMPACT OF BACTERIAL AND VIRAL INFECTIONS"], "deposited": {"date-parts": [[2013, 5, 23]], "date-time": "2013-05-23T12:49:32Z", "timestamp": 1369313372000}, "score": 30.052643, "issued": {"date-parts": [[2011, 5]]}, "references-count": 0, "alternative-id": ["10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A3730", "10.1164/ajrccm-conference.2011.B093"], "URL": "http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3730"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T04:53:02Z", "timestamp": 1574484782205}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2011, 4, 15]]}, "DOI": "10.1158/1538-7445.am2011-1296", "type": "proceedings-article", "created": {"date-parts": [[2012, 6, 27]], "date-time": "2012-06-27T21:11:34Z", "timestamp": 1340831494000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 1296: Safety, tolerability, and pharmacokinetics of the novel \u03b1v-integrin antibody DI17E6 in healthy subjects after ascending single intravenous doses"], "prefix": "10.1158", "author": [{"given": "Michael", "family": "Z\u00fchlsdorf", "sequence": "first", "affiliation": []}, {"given": "Andreas", "family": "Kovar", "sequence": "additional", "affiliation": []}, {"given": "Wolfgang", "family": "Uhl", "sequence": "additional", "affiliation": []}, {"given": "Ulf", "family": "Forssmann", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 13]]}, "event": {"name": "Proceedings: AACR 102nd Annual Meeting 2011\u2010\u2010 Apr 2\u20106, 2011; Orlando, FL"}, "container-title": ["Clinical Research"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2011-1296", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T21:34:04Z", "timestamp": 1558215244000}, "score": 29.506332, "issued": {"date-parts": [[2011, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2011-1296"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2011-1296"}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T21:43:45Z", "timestamp": 1574372625391}, "reference-count": 23, "publisher": "Wiley", "issue": "8", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 2587, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2008, 8]]}, "DOI": "10.1177/0091270008319793", "type": "journal-article", "created": {"date-parts": [[2008, 6, 3]], "date-time": "2008-06-03T01:03:23Z", "timestamp": 1212455003000}, "page": "926-934", "source": "Crossref", "is-referenced-by-count": 67, "title": ["Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers"], "prefix": "10.1002", "volume": "48", "author": [{"given": "Reiner", "family": "Frey", "sequence": "first", "affiliation": []}, {"given": "Wolfgang", "family": "M\u00fcck", "sequence": "additional", "affiliation": []}, {"given": "Sigrun", "family": "Unger", "sequence": "additional", "affiliation": []}, {"given": "Ulrike", "family": "Artmeier-Brandt", "sequence": "additional", "affiliation": []}, {"given": "Gerrit", "family": "Weimann", "sequence": "additional", "affiliation": []}, {"given": "Georg", "family": "Wensing", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2013, 3, 7]]}, "reference": [{"key": "10.1177/0091270008319793-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "343", "DOI": "10.7326/0003-4819-115-5-343", "article-title": "Survival in patients with primary pulmonary hypertension: results from a national prospective registry", "volume": "115", "author": "D'Alonzo", "year": "1991", "journal-title": "Ann Intern Med"}, {"key": "10.1177/0091270008319793-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "755", "DOI": "10.1038/nrd2038", "article-title": "NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential", "volume": "5", "author": "Evgenov", "year": "2006", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1177/0091270008319793-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "3203", "DOI": "10.1073/pnas.74.8.3203", "article-title": "Nitric oxide activates guanylate cyclase and increases guanosine 3\u2032:5\u2032-cyclic monophosphate levels in various tissue preparations", "volume": "74", "author": "Arnold", "year": "1977", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1177/0091270008319793-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1056/NEJM199507273330403", "article-title": "Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension", "volume": "333", "author": "Giaid", "year": "1995", "journal-title": "N Engl J Med"}, {"key": "10.1177/0091270008319793-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1545", "DOI": "10.1378/chest.109.6.1545", "article-title": "Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests", "volume": "109", "author": "Channick", "year": "1996", "journal-title": "Chest"}, {"key": "10.1177/0091270008319793-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "820", "DOI": "10.7326/0003-4819-124-9-199605010-00006", "article-title": "Aerosolized prostacyclin and iloprost in severe pulmonary hypertension", "volume": "124", "author": "Olschewski", "year": "1996", "journal-title": "Ann Intern Med"}, {"key": "10.1177/0091270008319793-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "417", "DOI": "10.1378/chest.129.2.417", "article-title": "Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension", "volume": "129", "author": "Klinger", "year": "2006", "journal-title": "Chest"}, {"key": "10.1177/0091270008319793-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "618", "DOI": "10.1161/01.RES.0000184694.03262.6d", "article-title": "Explaining the phenomenon of nitrate tolerance", "volume": "97", "author": "Munzel", "year": "2005", "journal-title": "Circ Res"}, {"key": "10.1177/0091270008319793-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "1759", "DOI": "10.1016/S0003-4975(96)00542-5", "article-title": "Rebound pulmonary hypertension after inhalation of nitric oxide", "volume": "62", "author": "Atz", "year": "1996", "journal-title": "Ann Thorac Surg"}, {"key": "10.1177/0091270008319793-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "2552", "DOI": "10.1172/JCI28371", "article-title": "Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels", "volume": "116", "author": "Stasch", "year": "2006", "journal-title": "J Clin Invest"}, {"key": "10.1177/0091270008319793-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "437", "DOI": "10.1016/j.healun.2007.01.035", "article-title": "Management of pulmonary arterial hypertension with a focus on combination therapies", "volume": "26", "author": "Benza", "year": "2007", "journal-title": "J Heart Lung Transplant"}, {"key": "10.1177/0091270008319793-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "689", "DOI": "10.1038/nrd2030", "article-title": "Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond", "volume": "5", "author": "Ghofrani", "year": "2006", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1177/0091270008319793-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "896", "DOI": "10.1056/NEJMoa012212", "article-title": "Bosentan therapy for pulmonary arterial hypertension", "volume": "346", "author": "Rubin", "year": "2002", "journal-title": "N Engl J Med"}, {"key": "10.1177/0091270008319793-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "2049", "DOI": "10.1016/j.jacc.2006.01.057", "article-title": "Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan", "volume": "47", "author": "Barst", "year": "2006", "journal-title": "J Am Coll Cardiol"}, {"key": "10.1177/0091270008319793-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "2148", "DOI": "10.1056/NEJMoa050010", "article-title": "Sildenafil citrate therapy for pulmonary arterial hypertension", "volume": "353", "author": "Galie", "year": "2005", "journal-title": "N Engl J Med"}, {"key": "10.1177/0091270008319793-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "800", "DOI": "10.1164/ajrccm.165.6.2106079", "article-title": "Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial", "volume": "165", "author": "Simonneau", "year": "2002", "journal-title": "Am J Respir Crit Care Med"}, {"key": "10.1177/0091270008319793-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "322", "DOI": "10.1056/NEJMoa020204", "article-title": "Inhaled iloprost for severe pulmonary hypertension", "volume": "347", "author": "Olschewski", "year": "2002", "journal-title": "N Engl J Med"}, {"key": "10.1177/0091270008319793-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "286", "DOI": "10.1161/CIRCULATIONAHA.105.581405", "article-title": "Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling", "volume": "113", "author": "Dumitrascu", "year": "2006", "journal-title": "Circulation"}, {"key": "10.1177/0091270008319793-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "1501", "DOI": "10.1016/j.rmed.2005.03.026", "article-title": "Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension", "volume": "99", "author": "Preston", "year": "2005", "journal-title": "Respir Med"}, {"key": "10.1177/0091270008319793-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "1207", "DOI": "10.4065/78.10.1207", "article-title": "Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy", "volume": "78", "author": "Bhatia", "year": "2003", "journal-title": "Mayo Clin Proc"}, {"key": "10.1177/0091270008319793-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "5", "DOI": "10.1023/A:1022150819223", "article-title": "The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension", "volume": "8", "author": "Michelakis", "year": "2003", "journal-title": "Heart Fail Rev"}, {"key": "10.1177/0091270008319793-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "296", "DOI": "10.1056/NEJM199602013340504", "article-title": "A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group", "volume": "334", "author": "Barst", "year": "1996", "journal-title": "N Engl J Med"}, {"key": "10.1177/0091270008319793-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "S8", "DOI": "10.1186/1471-2210-7-S1-S8", "article-title": "BAY 63-2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension", "volume": "7", "author": "Ghofrani", "year": "2007", "journal-title": "BMC Pharmacol"}], "container-title": ["The Journal of Clinical Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1177%2F0091270008319793", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1177/0091270008319793", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 1]], "date-time": "2018-08-01T18:32:21Z", "timestamp": 1533148341000}, "score": 28.946293, "issued": {"date-parts": [[2008, 8]]}, "references-count": 23, "journal-issue": {"published-print": {"date-parts": [[2008, 8]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1177/0091270008319793", "relation": {"cites": []}, "ISSN": ["0091-2700"], "issn-type": [{"value": "0091-2700", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T11:50:52Z", "timestamp": 1575287452249}, "reference-count": 12, "publisher": "Oxford University Press (OUP)", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Antimicrobial Chemotherapy"], "published-print": {"date-parts": [[2014, 3, 1]]}, "DOI": "10.1093/jac/dkt401", "type": "journal-article", "created": {"date-parts": [[2013, 10, 9]], "date-time": "2013-10-09T03:27:01Z", "timestamp": 1381289221000}, "page": "706-714", "source": "Crossref", "is-referenced-by-count": 28, "title": ["Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses"], "prefix": "10.1093", "volume": "69", "author": [{"given": "D.", "family": "Baldoni", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Gutierrez", "sequence": "additional", "affiliation": []}, {"given": "W.", "family": "Timmer", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Dingemanse", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2013, 10, 8]]}, "reference": [{"issue": "7", "key": "1_35069846", "doi-asserted-by": "publisher", "first-page": "526", "DOI": "10.1038/nrmicro2164", "volume": "7", "author": "Rupnik", "year": "2009", "journal-title": "Nature reviews. Microbiology", "ISSN": "http://id.crossref.org/issn/1740-1526", "issn-type": "print"}, {"issue": "7316", "key": "2_38140649", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1038/nature09397", "volume": "467", "author": "Kuehne", "year": "2010", "journal-title": "Nature; Physical Science (London)", "ISSN": "http://id.crossref.org/issn/1476-4687", "issn-type": "print"}, {"issue": "1", "key": "3_38770661", "doi-asserted-by": "publisher", "first-page": "17", "DOI": "10.1038/nrgastro.2010.190", "volume": "8", "author": "Ananthakrishnan", "year": "2011", "ISSN": "http://id.crossref.org/issn/1759-5053", "issn-type": "print"}, {"issue": "19", "key": "4_37692082", "doi-asserted-by": "publisher", "first-page": "4904", "DOI": "10.1128/JB.00445-10", "volume": "192", "year": "2010", "journal-title": "Journal of Bacteriology", "ISSN": "http://id.crossref.org/issn/0021-9193", "issn-type": "print"}, {"key": "5_46639093", "ISSN": "http://id.crossref.org/issn/1058-4838", "issn-type": "print", "volume": "55", "first-page": "88", "year": "2012", "journal-title": "Clinical Infectious Diseases", "DOI": "10.1093/cid/cis335", "doi-asserted-by": "crossref"}, {"key": "6_46639094", "ISSN": "http://id.crossref.org/issn/1058-4838", "issn-type": "print", "volume": "55", "first-page": "71", "year": "2012", "journal-title": "Clinical Infectious Diseases", "DOI": "10.1093/cid/cis355", "doi-asserted-by": "crossref"}, {"issue": "12", "key": "7_36064437", "doi-asserted-by": "publisher", "first-page": "1067", "DOI": "10.1111/j.1469-0691.2009.03099.x", "volume": "15", "author": "Bauer", "year": "2009", "journal-title": "Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases", "ISSN": "http://id.crossref.org/issn/1198-743X", "issn-type": "print"}, {"issue": "7", "key": "8_30941296", "doi-asserted-by": "publisher", "first-page": "2403", "DOI": "10.1128/AAC.00090-08", "volume": "52", "year": "2008", "journal-title": "Antimicrobial Agents and Chemotherapy", "ISSN": "http://id.crossref.org/issn/0066-4804", "issn-type": "print"}, {"key": "9_46043736", "ISSN": "http://id.crossref.org/issn/0277-0008", "issn-type": "print", "volume": "31", "first-page": "877", "year": "2011", "journal-title": "Pharmacotherapy", "DOI": "10.1592/phco.31.9.877", "doi-asserted-by": "crossref"}, {"issue": "4", "key": "10_37024209", "doi-asserted-by": "publisher", "first-page": "539", "DOI": "10.2217/fmb.10.20", "volume": "5", "author": "Poxton", "year": "2010", "ISSN": "http://id.crossref.org/issn/1746-0921", "issn-type": "print"}, {"key": "11_46639095", "ISSN": "http://id.crossref.org/issn/1058-4838", "issn-type": "print", "volume": "55", "first-page": "154", "year": "2012", "journal-title": "Clinical Infectious Diseases", "DOI": "10.1093/cid/cis462", "doi-asserted-by": "crossref"}, {"issue": "3", "key": "17_24913253", "doi-asserted-by": "publisher", "first-page": "1039", "DOI": "10.1177/009286159502900324", "volume": "29", "author": "Gough", "year": "1995", "journal-title": "Drug Information Journal", "ISSN": "http://id.crossref.org/issn/0092-8615", "issn-type": "print"}], "container-title": ["Journal of Antimicrobial Chemotherapy"], "language": "en", "link": [{"URL": "http://academic.oup.com/jac/article-pdf/69/3/706/2349042/dkt401.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 23]], "date-time": "2017-08-23T15:32:28Z", "timestamp": 1503502348000}, "score": 28.223341, "issued": {"date-parts": [[2013, 10, 8]]}, "references-count": 12, "journal-issue": {"published-online": {"date-parts": [[2014, 2, 12]]}, "published-print": {"date-parts": [[2014, 3, 1]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1093/jac/dkt401", "relation": {"cites": []}, "ISSN": ["0305-7453", "1460-2091"], "issn-type": [{"value": "0305-7453", "type": "print"}, {"value": "1460-2091", "type": "electronic"}], "subject": ["Pharmacology (medical)", "Pharmacology", "Infectious Diseases"]}, {"institution": {"name": "ISRCTN", "place": ["London, UK"], "acronym": ["-"]}, "indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T16:52:48Z", "timestamp": 1574527968745}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "content-domain": {"domain": ["www.isrctn.com"], "crossmark-restriction": true}, "DOI": "10.1186/isrctn11002924", "type": "dataset", "created": {"date-parts": [[2013, 1, 17]], "date-time": "2013-01-17T14:39:20Z", "timestamp": 1358433560000}, "update-policy": "http://dx.doi.org/10.1186/isrctn_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Clinical study to evaluate the safety and tolerability of immunoglobulin intravenous (human) 10% (NewGam) administered at high infusion rates to patients with primary immunodeficiency diseases"], "prefix": "10.1186", "author": [{"given": "Wolfgang", "family": "Frenzel", "sequence": "first", "affiliation": []}], "member": "297", "content-created": {"date-parts": [[2013, 1, 17]]}, "container-title": ["http://isrctn.org/>"], "deposited": {"date-parts": [[2015, 6, 12]], "date-time": "2015-06-12T13:52:43Z", "timestamp": 1434117163000}, "score": 28.022257, "issued": {"date-parts": [[2013, 1, 17]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1186/isrctn11002924"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T15:24:42Z", "timestamp": 1574436282228}, "publisher-location": "Vienna", "reference-count": 143, "publisher": "Springer Vienna", "isbn-type": [{"value": "9783211252239", "type": "print"}, {"value": "9783211694596", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2008]]}, "DOI": "10.1007/978-3-211-69459-6_16", "type": "book-chapter", "created": {"date-parts": [[2010, 6, 11]], "date-time": "2010-06-11T14:43:04Z", "timestamp": 1276267384000}, "page": "407-431", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations"], "prefix": "10.1007", "author": [{"given": "Wolfgang", "family": "Jelkmann", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "16_CR1", "first-page": "3582", "volume": "252", "author": "A. Abuchowski", "year": "1977", "unstructured": "Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977b) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252: 3582\u20133586", "journal-title": "J Biol Chem"}, {"key": "16_CR2", "first-page": "3578", "volume": "252", "author": "A. Abuchowski", "year": "1977", "unstructured": "Abuchowski A, van Es T, Palczuk NC, Davis FF (1977a) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252: 3578\u20133581", "journal-title": "J Biol Chem"}, {"key": "16_CR3", "first-page": "539", "volume": "43", "author": "V.N. Acharya", "year": "1995", "unstructured": "Acharya VN, Sinha DK, Almeida AF, Pathare AV (1995) Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. J Assoc Physicians India 43: 539\u2013542", "journal-title": "J Assoc Physicians India"}, {"key": "16_CR4", "doi-asserted-by": "publisher", "first-page": "349", "DOI": "10.1146/annurev.me.41.020190.002025", "volume": "41", "author": "J.W. Adamson", "year": "1990", "unstructured": "Adamson JW, Eschbach JW (1990) Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 41: 349\u2013360", "journal-title": "Annu Rev Med"}, {"key": "16_CR5", "doi-asserted-by": "publisher", "first-page": "80", "DOI": "10.1093/ndt/14.suppl_2.80", "volume": "14", "author": "F.P. Barbone", "year": "1999", "unstructured": "Barbone FP, Johnson DL, Farrell FX, Collins A, Middleton SA, McMahon FJ, Tullai J, Jolliffe LK (1999) New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 14: 80\u201384", "journal-title": "Nephrol Dial Transplant"}, {"key": "16_CR6", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1007/BF01737420", "volume": "68", "author": "G. Barosi", "year": "1994", "unstructured": "Barosi G (1994) Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 68: 215\u2013223", "journal-title": "Ann Hematol"}, {"key": "16_CR7", "doi-asserted-by": "crossref", "first-page": "781", "DOI": "10.1038/bjc.1998.579", "volume": "78", "author": "G. Barosi", "year": "1998", "unstructured": "Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78: 781\u2013787", "journal-title": "Br J Cancer"}, {"key": "16_CR8", "first-page": "2010", "volume": "82", "author": "Y. Beguin", "year": "1993", "unstructured": "Beguin Y, Loo M, R\u2019Zik S, Sautois B, Lejeune F, Rorive G, Fillet G (1993) Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82: 2010\u20132016", "journal-title": "Blood"}, {"key": "16_CR9", "doi-asserted-by": "publisher", "first-page": "1403", "DOI": "10.1056/NEJMoa040528", "volume": "351", "author": "C.L. Bennett", "year": "2004", "unstructured": "Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N (2004) Pure red-cell aplasia and epoetin therapy. N Engl J Med 351: 1403\u20131408", "journal-title": "N Engl J Med"}, {"key": "16_CR10", "doi-asserted-by": "publisher", "first-page": "125", "DOI": "10.1111/j.1365-2796.1991.tb00319.x", "volume": "229", "author": "B. Berglund", "year": "1991", "unstructured": "Berglund B, Ekblom B (1991) Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 229: 125\u2013130", "journal-title": "J Intern Med"}, {"key": "16_CR11", "doi-asserted-by": "publisher", "first-page": "2201", "DOI": "10.1016/j.ejca.2004.07.015", "volume": "40", "author": "C. Bokemeyer", "year": "2004", "unstructured": "Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, \u00d6sterborg A, Repetto L, Soubeyran P (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40: 2201\u20132216", "journal-title": "Eur J Cancer"}, {"key": "16_CR12", "doi-asserted-by": "publisher", "first-page": "2346", "DOI": "10.1111/j.1523-1755.2005.00340.x", "volume": "67", "author": "K. Boven", "year": "2005", "unstructured": "Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N (2005) The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67: 2346\u20132353", "journal-title": "Kidney Int"}, {"key": "16_CR13", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1046/j.1525-1594.2002.06844.x", "volume": "26", "author": "A. Bren", "year": "2002", "unstructured": "Bren A, Kandus A, Varl J, Buturovic J, Ponikvar R, Kveder R, Primozic S, Ivanovich P (2002) A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study. Artif Organs 26: 91\u201397", "journal-title": "Artif Organs"}, {"key": "16_CR14", "doi-asserted-by": "publisher", "first-page": "14907", "DOI": "10.1073/pnas.0406491101", "volume": "101", "author": "M. Brines", "year": "2004", "unstructured": "Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 101: 14907\u201314912", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "16_CR15", "first-page": "499", "volume": "34", "author": "J. Brockm\u00f6ller", "year": "1992", "unstructured": "Brockm\u00f6ller J, K\u00f6chling J, Weber W, Looby M, Roots I, Neumayer H-H (1992) The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 34: 499\u2013508", "journal-title": "Br J Clin Pharmacol"}, {"key": "16_CR16", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.1016/0003-9861(88)90135-X", "volume": "265", "author": "V.C. Broudy", "year": "1988", "unstructured": "Broudy VC, Tait JF, Powell JS (1988) Recombinant human erythropoietin: purification and analysis of carbohydrate linkage. Arch Biochem Biophys 265: 329\u2013336", "journal-title": "Arch Biochem Biophys"}, {"key": "16_CR17", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1016/S1357-4310(00)01677-4", "volume": "6", "author": "J.M. Brown", "year": "2000", "unstructured": "Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6: 157\u2013162", "journal-title": "Mol Med Today"}, {"key": "16_CR18", "doi-asserted-by": "publisher", "first-page": "469", "DOI": "10.1056/NEJMoa011931", "volume": "346", "author": "N. Casadevall", "year": "2002", "unstructured": "Casadevall N, Nataf J, Viron B, Klota A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469\u2013475", "journal-title": "N Engl J Med"}, {"key": "16_CR19", "doi-asserted-by": "publisher", "first-page": "477", "DOI": "10.1358/dot.2003.39.7.799441", "volume": "39", "author": "A. Cases", "year": "2003", "unstructured": "Cases A (2003) Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs of Today 39: 477\u2013495", "journal-title": "Drugs of Today"}, {"key": "16_CR20", "first-page": "2139", "volume": "91", "author": "M. Cazzola", "year": "1998", "unstructured": "Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y (1998) Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 91: 2139\u20132145", "journal-title": "Blood"}, {"key": "16_CR21", "first-page": "4248", "volume": "89", "author": "M. Cazzola", "year": "1997", "unstructured": "Cazzola M, Mercuriali F, Brugnara C (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 89: 4248\u20134267", "journal-title": "Blood"}, {"key": "16_CR22", "first-page": "4446", "volume": "86", "author": "M. Cazzola", "year": "1995", "unstructured": "Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller ZL, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin\u2019s lymphoma: dose finding and identification of predictors of response. Blood 86: 4446\u20134453", "journal-title": "Blood"}, {"key": "16_CR23", "doi-asserted-by": "publisher", "first-page": "8", "DOI": "10.1093/ndt/17.suppl_1.8", "volume": "17", "author": "A. Cerami", "year": "2002", "unstructured": "Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM (2002) Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant 17: 8\u201312", "journal-title": "Nephrol Dial Transplant"}, {"key": "16_CR24", "doi-asserted-by": "publisher", "first-page": "425", "DOI": "10.1016/S0301-472X(01)00614-2", "volume": "29", "author": "S.H. Chapel", "year": "2001", "unstructured": "Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA (2001) Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 29: 425\u2013431", "journal-title": "Exp Hematol"}, {"key": "16_CR25", "doi-asserted-by": "publisher", "first-page": "412", "DOI": "10.1016/S0009-9236(98)90072-8", "volume": "64", "author": "W.K. Cheung", "year": "1998", "unstructured": "Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC (1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64: 412\u2013423", "journal-title": "Clin Pharmacol Ther"}, {"key": "16_CR26", "doi-asserted-by": "publisher", "first-page": "141", "DOI": "10.2174/1568006033481483", "volume": "3", "author": "Z.Z. Chong", "year": "2003", "unstructured": "Chong ZZ, Kang JQ, Maiese K (2003) Erythropoietin: cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 3: 141\u2013154", "journal-title": "Curr Drug Targets Cardiovasc Haematol Disord"}, {"key": "16_CR27", "doi-asserted-by": "publisher", "first-page": "21969", "DOI": "10.1074/jbc.271.36.21969", "volume": "271", "author": "R. Clark", "year": "1996", "unstructured": "Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G, Chang S, Chu H, Mukku V, Canova-Davis E, Somers T, Cronin M, Winkler M, Wells JA (1996) Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271: 21969\u201321977", "journal-title": "J Biol Chem"}, {"key": "16_CR28", "doi-asserted-by": "publisher", "first-page": "511", "DOI": "10.1093/glycob/10.5.511", "volume": "10", "author": "D. Cointe", "year": "2000", "unstructured": "Cointe D, Beliard R, Jorieux S, Leroy Y, Glacet A, Verbert A, Bourel D, Chirat F (2000) Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties. Glycobiology 10: 511\u2013519", "journal-title": "Glycobiology"}, {"key": "16_CR29", "first-page": "F939", "volume": "263", "author": "G.A. Coles", "year": "1992", "unstructured": "Coles GA, Liberek T, Davies ME, Robinson M, Jones J, Thomas G, Davies M, MacDougall IC, Williams JD (1992) Estimation of erythropoietin secretion rate in normal and uremic subjects. Am J Physiol 263: F939\u2013F944", "journal-title": "Am J Physiol"}, {"key": "16_CR30", "first-page": "113", "volume": "70", "author": "P.M. Cotes", "year": "1989", "unstructured": "Cotes PM, Pippard MJ, Reid CD, Winearls CG, Oliver DO, Royston JP (1989) Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 70: 113\u2013137", "journal-title": "Q J Med"}, {"key": "16_CR31", "doi-asserted-by": "publisher", "first-page": "1067", "DOI": "10.2165/00003495-200363110-00003", "volume": "63", "author": "R.S. Cvetkovic", "year": "2003", "unstructured": "Cvetkovic RS, Goa KL (2003) Darbepoetin alfa: in patients with chemotherapyrelated anaemia. Drugs 63: 1067\u20131074", "journal-title": "Drugs"}, {"key": "16_CR32", "doi-asserted-by": "publisher", "first-page": "14524", "DOI": "10.1021/bi0265022", "volume": "41", "author": "R.J. Darling", "year": "2002", "unstructured": "Darling RJ, Kuchibhotla U, Glaesner W, Micanovic R, Witcher DR, Beals JM (2002) Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions. Biochemistry 41: 14524\u201314531", "journal-title": "Biochemistry"}, {"key": "16_CR33", "doi-asserted-by": "publisher", "first-page": "489", "DOI": "10.1038/46809", "volume": "401", "author": "R. Maria De", "year": "1999", "unstructured": "De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F, Srinivasula SM, Alnemri ES, Testa U, Peschle C (1999) Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 401: 489\u2013493", "journal-title": "Nature"}, {"key": "16_CR34", "doi-asserted-by": "crossref", "first-page": "3412", "DOI": "10.1200/JCO.1998.16.10.3412", "volume": "16", "author": "G.D. Demetri", "year": "1998", "unstructured": "Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16: 3412\u20133425", "journal-title": "J Clin Oncol"}, {"key": "16_CR35", "doi-asserted-by": "publisher", "first-page": "265", "DOI": "10.1111/j.1365-2141.1987.tb06852.x", "volume": "65", "author": "E.N. Dessypris", "year": "1987", "unstructured": "Dessypris EN, Gleaton JH, Armstrong OL (1987) Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol 65: 265\u2013269", "journal-title": "Br J Haematol"}, {"key": "16_CR36", "first-page": "503a", "volume": "102", "author": "A. Dmoszynska", "year": "2003", "unstructured": "Dmoszynska A, Kloczko J, Rokicka M, Hellmann A, Spicka I, Henry D (2003) CERA (Continuous erythropoiesis receptor activator) produces a dose-related response in patients with multiple myeloma: an exploratory phase I-II doseescalation study. Blood 102: 503a (Abstr 1830)", "journal-title": "Blood"}, {"key": "16_CR37", "first-page": "713", "volume": "102", "author": "F.C. Dougherty", "year": "2003", "unstructured": "Dougherty FC, Reigner B, Jordan P, Pannier A (2003) CERA (Continuous erythropoiesis receptor activator) demonstrates dose-dependent activity and is well tolerated in phase I multiple ascending dose studies. Blood 102: 713", "journal-title": "Blood"}, {"key": "16_CR38", "doi-asserted-by": "publisher", "first-page": "299", "DOI": "10.2165/00003495-199651020-00008", "volume": "51", "author": "C.J. Dunn", "year": "1996", "unstructured": "Dunn CJ, Markham A (1996) Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs 51: 299\u2013318", "journal-title": "Drugs"}, {"key": "16_CR39", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1054/bjoc.2001.1746", "volume": "84", "author": "J.C. Egrie", "year": "2001", "unstructured": "Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84: 3\u201310", "journal-title": "Br J Cancer"}, {"key": "16_CR40", "doi-asserted-by": "publisher", "first-page": "290", "DOI": "10.1016/S0301-472X(03)00006-7", "volume": "31", "author": "J.C. Egrie", "year": "2003", "unstructured": "Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31: 290\u2013299", "journal-title": "Exp Hematol"}, {"key": "16_CR41", "doi-asserted-by": "crossref", "first-page": "495", "DOI": "10.1007/BF03402029", "volume": "8", "author": "H. Ehrenreich", "year": "2002", "unstructured": "Ehrenreich H, Hasselblatt M, Dembrowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck H-H, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, R\u00fcther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sir\u00e9n A-L (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495\u2013505", "journal-title": "Mol Med"}, {"key": "16_CR42", "doi-asserted-by": "publisher", "first-page": "1146", "DOI": "10.1016/j.exphem.2004.08.004", "volume": "32", "author": "S. Elliott", "year": "2004", "unstructured": "Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I (2004) Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32: 1146\u20131155", "journal-title": "Exp Hematol"}, {"key": "16_CR43", "doi-asserted-by": "publisher", "first-page": "414", "DOI": "10.1038/nbt799", "volume": "21", "author": "S. Elliott", "year": "2003", "unstructured": "Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21: 414\u2013421", "journal-title": "Nat Biotechnol"}, {"key": "16_CR44", "doi-asserted-by": "crossref", "first-page": "291", "DOI": "10.1056/NEJM198408023110504", "volume": "311", "author": "S.H. Embury", "year": "1984", "unstructured": "Embury SH, Garcia JF, Mohandas N, Pennathur DR, Clark MR (1984) Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. N Engl J Med 311: 291\u2013295", "journal-title": "N Engl J Med"}, {"key": "16_CR45", "doi-asserted-by": "crossref", "first-page": "73", "DOI": "10.1056/NEJM198701083160203", "volume": "316", "author": "J.W. Eschbach", "year": "1987", "unstructured": "Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73\u201378", "journal-title": "N Engl J Med"}, {"issue": "[Suppl 5]", "key": "16_CR46", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1634/theoncologist.9-90005-18", "volume": "9", "author": "F. Farrell", "year": "2004", "unstructured": "Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 [Suppl 5]: 18\u201330", "journal-title": "Oncologist"}, {"key": "16_CR47", "first-page": "81", "volume": "5", "author": "T. Fjornes", "year": "1998", "unstructured": "Fjornes T, Wiedemann GJ, Sack K, Jelkmann W (1998) Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy. Oncol Rep 5: 81\u201386", "journal-title": "Oncol Rep"}, {"key": "16_CR48", "doi-asserted-by": "crossref", "first-page": "557", "DOI": "10.1038/clpt.1990.76", "volume": "47", "author": "K.K. Flaharty", "year": "1990", "unstructured": "Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH (1990) Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47: 557\u2013564", "journal-title": "Clin Pharmacol Ther"}, {"key": "16_CR49", "doi-asserted-by": "publisher", "first-page": "3300", "DOI": "10.1182/blood-2003-11-3852", "volume": "103", "author": "G. Gao", "year": "2004", "unstructured": "Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B, Bagg A, Zhang Y, Wilson JM (2004) Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103: 3300\u20133302", "journal-title": "Blood"}, {"issue": "[Suppl 2]", "key": "16_CR50", "first-page": "20", "volume": "34", "author": "J. Glaspy", "year": "1997", "unstructured": "Glaspy J (1997) The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol 34 [Suppl 2]: 20\u201326", "journal-title": "Semin Hematol"}, {"key": "16_CR51", "doi-asserted-by": "crossref", "first-page": "1218", "DOI": "10.1200/JCO.1997.15.3.1218", "volume": "15", "author": "J. Glaspy", "year": "1997", "unstructured": "Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan RS (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218\u20131234", "journal-title": "J Clin Oncol"}, {"key": "16_CR52", "unstructured": "Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, Lloyd R, Berg R, Austin M, Rossi G (2005) The effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer (in press)", "DOI": "10.1016/j.ejca.2005.01.021", "doi-asserted-by": "crossref"}, {"key": "16_CR53", "doi-asserted-by": "publisher", "first-page": "268", "DOI": "10.1038/sj.bjc.6600465", "volume": "87", "author": "J.A. Glaspy", "year": "2002", "unstructured": "Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O\u2019Byrne J, Rossi G, Colowick AB (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87: 268\u2013276", "journal-title": "Br J Cancer"}, {"key": "16_CR54", "doi-asserted-by": "publisher", "first-page": "81", "DOI": "10.1023/A:1026466408042", "volume": "16", "author": "E. Grabenhorst", "year": "1999", "unstructured": "Grabenhorst E, Schlenke P, Pohl S, Nimtz M, Conradt HS (1999) Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells. Glycoconjugate J 16: 81\u201397", "journal-title": "Glycoconjugate J"}, {"key": "16_CR55", "doi-asserted-by": "publisher", "first-page": "6327", "DOI": "10.1074/jbc.M412134200", "volume": "280", "author": "M.J. Grace", "year": "2005", "unstructured": "Grace MJ, Lee S, Bradshaw S, Chapman J, Spond J, Cox S, Delorenzo M, Brassard D, Wylie D, Cannon-Carlson S, Cullen C, Indelicato S, Voloch M, Bordens R (2005) Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem 280: 6327\u20136336", "journal-title": "J Biol Chem"}, {"key": "16_CR56", "doi-asserted-by": "crossref", "first-page": "702", "DOI": "10.1038/clpt.1991.210", "volume": "50", "author": "C.E. Halstenson", "year": "1991", "unstructured": "Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50: 702\u2013712", "journal-title": "Clin Pharmacol Ther"}, {"key": "16_CR57", "doi-asserted-by": "publisher", "first-page": "253", "DOI": "10.1016/S1045-1056(05)80044-2", "volume": "20", "author": "T. Hayakawa", "year": "1992", "unstructured": "Hayakawa T, Wada M, Mizuno K, Abe S, Miyashita M, Ueda M (1992) In vivo biological activities of recombinant human erythropoietin analogues produced by CHO cells, BHK cells and C127 cells. Biologicals 20: 253\u2013257", "journal-title": "Biologicals"}, {"issue": "[Suppl 1]", "key": "16_CR58", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1054/bjoc.2001.1747", "volume": "84", "author": "A.C. Heatherington", "year": "2001", "unstructured": "Heatherington AC, Schuller J, Mercer AJ (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 84 [Suppl 1]: 11\u201316", "journal-title": "Br J Cancer"}, {"key": "16_CR59", "doi-asserted-by": "publisher", "first-page": "1255", "DOI": "10.1016/S0140-6736(03)14567-9", "volume": "362", "author": "M. Henke", "year": "2003", "unstructured": "Henke M, Laszing R, R\u00fcbe C, Sch\u00e4fer U, Haase K-D, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255\u20131260", "journal-title": "Lancet"}, {"key": "16_CR60", "doi-asserted-by": "publisher", "first-page": "262", "DOI": "10.1001/archinte.164.3.262", "volume": "164", "author": "D.H. Henry", "year": "2004", "unstructured": "Henry DH, Bowers P, Romano MT, Provenzano R (2004) Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 164: 262\u2013276", "journal-title": "Arch Intern Med"}, {"key": "16_CR61", "doi-asserted-by": "publisher", "first-page": "297", "DOI": "10.1016/S1387-2656(08)70055-3", "volume": "1", "author": "N. Inoue", "year": "1995", "unstructured": "Inoue N, Takeuchi M, Ohashi H, Suzuki T (1995) The production of recombinant human erythropoietin. Biotechnol Annu Rev 1: 297\u2013313", "journal-title": "Biotechnol Annu Rev"}, {"key": "16_CR62", "doi-asserted-by": "publisher", "first-page": "401", "DOI": "10.1016/0002-9343(93)90151-E", "volume": "94", "author": "T. Ishimitsu", "year": "1993", "unstructured": "Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S (1993) Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 94: 401\u2013406", "journal-title": "Am J Med"}, {"key": "16_CR63", "doi-asserted-by": "publisher", "first-page": "806", "DOI": "10.1038/313806a0", "volume": "313", "author": "K. Jacobs", "year": "1985", "unstructured": "Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T (1985) Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806\u2013810", "journal-title": "Nature"}, {"key": "16_CR64", "doi-asserted-by": "publisher", "first-page": "265", "DOI": "10.1034/j.1600-0609.2002.02813.x", "volume": "69", "author": "W. Jelkmann", "year": "2002", "unstructured": "Jelkmann W (2002) The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 69: 265\u2013274", "journal-title": "Eur J Haematol"}, {"key": "16_CR65", "author": "W. Jelkmann", "year": "1989", "unstructured": "Jelkmann W, Gross A (1989) Erythropoietin. Springer, Berlin Heidelberg New York", "volume-title": "Erythropoietin", "DOI": "10.1007/978-3-642-83745-6", "doi-asserted-by": "crossref"}, {"key": "16_CR66", "doi-asserted-by": "crossref", "first-page": "449", "DOI": "10.1152/physrev.1992.72.2.449", "volume": "72", "author": "W. Jelkmann", "year": "1992", "unstructured": "Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72: 449\u2013489", "journal-title": "Physiol Rev"}, {"key": "16_CR67", "doi-asserted-by": "publisher", "first-page": "673", "DOI": "10.1007/s00277-004-0911-6", "volume": "83", "author": "W. Jelkmann", "year": "2004", "unstructured": "Jelkmann W, Wagner K (2004) Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83: 673\u2013686", "journal-title": "Ann Hematol"}, {"key": "16_CR68", "doi-asserted-by": "publisher", "first-page": "403", "DOI": "10.1007/BF01648581", "volume": "68", "author": "W. Jelkmann", "year": "1990", "unstructured": "Jelkmann W, Wiedemann G (1990) Serum erythropoietin level: relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow. Klin Wochenschr 68: 403\u2013407", "journal-title": "Klin Wochenschr"}, {"key": "16_CR69", "first-page": "177", "volume": "5", "author": "J.D. Jensen", "year": "1994", "unstructured": "Jensen JD, Madsen JK, Jensen LW, Pedersen EB (1994) Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 5: 177\u2013185", "journal-title": "J Am Soc Nephrol"}, {"key": "16_CR70", "first-page": "91", "volume": "16", "author": "N.L. Jumbe", "year": "2002", "unstructured": "Jumbe NL (2002) Erythropoietic agents as neurotherapeutic agents: what barriers exist? Oncology (Hungtingt) 16: 91\u2013107", "journal-title": "Oncology (Hungtingt)"}, {"key": "16_CR71", "doi-asserted-by": "publisher", "first-page": "527", "DOI": "10.1016/S0095-5108(05)70037-3", "volume": "27", "author": "S.E. Juul", "year": "2000", "unstructured": "Juul SE (2000) Nonerythropoietic roles of erythropoietin in the fetus and neonate. Clin Perinatol 27: 527\u2013541", "journal-title": "Clin Perinatol"}, {"key": "16_CR72", "doi-asserted-by": "publisher", "first-page": "393", "DOI": "10.1159/000186955", "volume": "61", "author": "D. Kampf", "year": "1992", "unstructured": "Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M (1992) Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 61: 393\u2013398", "journal-title": "Nephron"}, {"key": "16_CR73", "doi-asserted-by": "crossref", "first-page": "345", "DOI": "10.1093/oxfordjournals.ndt.a091888", "volume": "4", "author": "J. Kindler", "year": "1989", "unstructured": "Kindler J, Eckardt KU, Ehmer B, Jandeleit K, Kurtz A, Schreiber A, Scigalla P, Sieberth HG (1989) Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 4: 345\u2013349", "journal-title": "Nephrol Dial Transplant"}, {"key": "16_CR74", "doi-asserted-by": "publisher", "first-page": "729", "DOI": "10.1016/0092-8674(95)90351-8", "volume": "80", "author": "U. Klingmuller", "year": "1995", "unstructured": "Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80: 729\u2013738", "journal-title": "Cell"}, {"key": "16_CR75", "doi-asserted-by": "publisher", "first-page": "2026", "DOI": "10.1016/S0959-8049(03)00456-8", "volume": "39", "author": "D. Kotasek", "year": "2003", "unstructured": "Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39: 2026\u20132034", "journal-title": "Eur J Cancer"}, {"key": "16_CR76", "doi-asserted-by": "publisher", "first-page": "378", "DOI": "10.1126/science.2326648", "volume": "248", "author": "M.J. Koury", "year": "1990", "unstructured": "Koury MJ, Bondurant MC (1990) Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248: 378\u2013381", "journal-title": "Science"}, {"key": "16_CR77", "doi-asserted-by": "publisher", "first-page": "649", "DOI": "10.1111/j.1432-1033.1992.tb17466.x", "volume": "210", "author": "M.J. Koury", "year": "1992", "unstructured": "Koury MJ, Bondurant MC (1992) The molecular mechanism of erythropoietin action. Eur J Biochem 210: 649\u2013663", "journal-title": "Eur J Biochem"}, {"key": "16_CR78", "first-page": "419", "volume": "77", "author": "S.B. Krantz", "year": "1991", "unstructured": "Krantz SB (1991) Erythropoietin. Blood 77: 419\u2013434", "journal-title": "Blood"}, {"key": "16_CR79", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1177/107327489800502s07", "volume": "5", "author": "J.S. Lee", "year": "1998", "unstructured": "Lee JS (1998) The use of erythropoietin in radiation oncology. Cancer Control 5 [Suppl]: 33\u201339", "journal-title": "Cancer Control"}, {"key": "16_CR80", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1126/science.1098313", "volume": "305", "author": "M. Leist", "year": "2004", "unstructured": "Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239\u2013242", "journal-title": "Science"}, {"key": "16_CR81", "doi-asserted-by": "publisher", "first-page": "459", "DOI": "10.1016/S1470-2045(03)01163-X", "volume": "4", "author": "B. Leyland-Jones", "year": "2003", "unstructured": "Leyland-Jones B, BEST Investigators and Study Group (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459\u2013460", "journal-title": "Lancet Oncol"}, {"key": "16_CR82", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.7326/0003-4819-110-2-108", "volume": "110", "author": "V.S. Lim", "year": "1989", "unstructured": "Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J (1989) Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110: 108\u2013114", "journal-title": "Ann Intern Med"}, {"key": "16_CR83", "doi-asserted-by": "publisher", "first-page": "169", "DOI": "10.1002/hon.722", "volume": "21", "author": "T.J. Littlewood", "year": "2003", "unstructured": "Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M (2003) Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 21: 169\u2013180", "journal-title": "Hematol Oncol"}, {"key": "16_CR84", "doi-asserted-by": "crossref", "first-page": "464", "DOI": "10.1126/science.273.5274.464", "volume": "273", "author": "O Livnah", "year": "1996", "unstructured": "Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA (1996) Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273: 464\u2013471", "journal-title": "Science"}, {"key": "16_CR85", "doi-asserted-by": "publisher", "first-page": "741", "DOI": "10.1046/j.1523-1755.2001.060002741.x", "volume": "60", "author": "F. Locatelli", "year": "2001", "unstructured": "Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ (2001) Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60: 741\u2013747", "journal-title": "Kidney Int"}, {"key": "16_CR86", "first-page": "47", "volume": "33", "author": "S.F. Lui", "year": "1990", "unstructured": "Lui SF, Chung WW, Leung CB, Chan K, Lai KN (1990) Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 33: 47\u201351", "journal-title": "Clin Nephrol"}, {"key": "16_CR87", "first-page": "375", "volume": "20", "author": "I.C. MacDougall", "year": "2000", "unstructured": "MacDougall IC (2000) Novel erythropoiesis stimulating protein. Semin Nephrol 20: 375\u2013381", "journal-title": "Semin Nephrol"}, {"key": "16_CR88", "first-page": "769A", "volume": "14", "author": "I.C. MacDougall", "year": "2003", "unstructured": "MacDougall IC, Bailon P, Tare N, Pahlke W, Pill J, Brandt M (2003) CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol 14: 769A", "journal-title": "J Am Soc Nephrol"}, {"key": "16_CR89", "first-page": "2392", "volume": "10", "author": "I.C. MacDougall", "year": "1999", "unstructured": "MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392\u20132395", "journal-title": "J Am Soc Nephrol"}, {"key": "16_CR90", "doi-asserted-by": "publisher", "first-page": "425", "DOI": "10.1016/S0140-6736(89)90014-7", "volume": "1", "author": "I.C. MacDougall", "year": "1989", "unstructured": "MacDougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD (1989) Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1: 425\u2013427", "journal-title": "Lancet"}, {"key": "16_CR91", "first-page": "225", "volume": "15", "author": "H.H. Marti", "year": "2000", "unstructured": "Marti HH, Bernaudin M, Petit E, Bauer C (2000) Neuroprotection and angiogenesis: Dual role of erythropoietin in brain ischemia. News Physiol Sci 15: 225\u2013229", "journal-title": "News Physiol Sci"}, {"key": "16_CR92", "first-page": "1", "volume": "70", "author": "S. Masuda", "year": "1999", "unstructured": "Masuda S, Nagao M, Sasaki R (1999) Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 70: 1\u20136", "journal-title": "Int J Hematol"}, {"key": "16_CR93", "first-page": "1718", "volume": "76", "author": "F.G. McMahon", "year": "1990", "unstructured": "McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL (1990) Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76: 1718\u20131722", "journal-title": "Blood"}, {"key": "16_CR94", "first-page": "R1829", "volume": "273", "author": "K.M. Moritz", "year": "1997", "unstructured": "Moritz KM, Lim GB, Wintour EM (1997) Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 273: R1829\u2013R1844", "journal-title": "Am J Physiol"}, {"key": "16_CR95", "doi-asserted-by": "publisher", "first-page": "343", "DOI": "10.1016/1357-4310(96)81800-4", "volume": "2", "author": "N. Naffakh", "year": "1996", "unstructured": "Naffakh N, Danos O (1996) Gene transfer for erythropoiesis enhancement. Mol Med Today 2: 343\u2013348", "journal-title": "Mol Med Today"}, {"key": "16_CR96", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1111/j.1600-0773.1990.tb00710.x", "volume": "66", "author": "O.J. Nielsen", "year": "1990", "unstructured": "Nielsen OJ (1990) Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol 66: 83\u201386", "journal-title": "Pharmacol Toxicol"}, {"key": "16_CR97", "doi-asserted-by": "publisher", "first-page": "39", "DOI": "10.1111/j.1432-1033.1993.tb17732.x", "volume": "213", "author": "M. Nimtz", "year": "1993", "unstructured": "Nimtz M, Martin W, Wray V, Kloppel KD, Augustin J, Conradt HS (1993) Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur J Biochem 213: 39\u201356", "journal-title": "Eur J Biochem"}, {"key": "16_CR98", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1016/0014-5793(95)00473-M", "volume": "365", "author": "M. Nimtz", "year": "1995", "unstructured": "Nimtz M, Wray V, Rudiger A, Conradt HS (1995) Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. FEBS Lett 365: 203\u2013208", "journal-title": "FEBS Lett"}, {"issue": "[Suppl 1]", "key": "16_CR99", "first-page": "S19", "volume": "15", "author": "M.R. Nowrousian", "year": "1998", "unstructured": "Nowrousian MR (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15 [Suppl 1]: S19\u2013S28", "journal-title": "Med Oncol"}, {"key": "16_CR100", "author": "H. Pagel", "year": "1992", "unstructured": "Pagel H, Weiss C, Jelkmann W (1992) Pathophysiology and pharmacology of erythropoietin. Springer, Berlin Heidelberg", "volume-title": "Pathophysiology and pharmacology of erythropoietin", "DOI": "10.1007/978-3-642-77074-6", "doi-asserted-by": "crossref"}, {"key": "16_CR101", "doi-asserted-by": "crossref", "first-page": "999", "DOI": "10.1172/JCI18200", "volume": "112", "author": "C.J. Parsa", "year": "2003", "unstructured": "Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999\u20131007", "journal-title": "J Clin Invest"}, {"key": "16_CR102", "doi-asserted-by": "publisher", "first-page": "1681", "DOI": "10.1021/bi9524272", "volume": "35", "author": "J.S. Philo", "year": "1996", "unstructured": "Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J (1996) Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one highaffinity and one low-affinity interaction. Biochemistry 35: 1681\u20131691", "journal-title": "Biochemistry"}, {"key": "16_CR103", "doi-asserted-by": "publisher", "first-page": "12156", "DOI": "10.1073/pnas.96.21.12156", "volume": "96", "author": "S.A. Qureshi", "year": "1999", "unstructured": "Qureshi SA, Kim RM, Konteatis Z, Biazzo DE, Motamedi H, Rodrigues R, Boice JA, Calaycay JR, Bednarek MA, Griffin P, Gao YD, Chapman K, Mark DF (1999) Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 96: 12156\u201312161", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "16_CR104", "doi-asserted-by": "publisher", "first-page": "948", "DOI": "10.1002/(SICI)1096-9888(199709)32:9<948::AID-JMS551>3.0.CO;2-C", "volume": "32", "author": "H. Rahbek-Nielsen", "year": "1997", "unstructured": "Rahbek-Nielsen H, Roepstorff P, Reischl H, Wozny M, Koll H, Haselbeck A (1997) Glycopeptide profiling of human urinary erythropoietin by matrixassisted laser desorption/ionization mass spectrometry. J Mass Spectrometry 32: 948\u2013958", "journal-title": "J Mass Spectrometry"}, {"key": "16_CR105", "first-page": "17156", "volume": "262", "author": "MA Recny", "year": "1987", "unstructured": "Recny MA, Scoble HA, Kim Y (1987) Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 262: 17156\u201317163", "journal-title": "J Biol Chem"}, {"key": "16_CR106", "doi-asserted-by": "publisher", "first-page": "1881", "DOI": "10.1089/hum.1997.8.16-1881", "volume": "8", "author": "C. Rinsch", "year": "1997", "unstructured": "Rinsch C, Regulier E, Deglon N, Dalle B, Beuzard Y, Aebischer P (1997) A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 8: 1881\u20131889", "journal-title": "Hum Gene Ther"}, {"key": "16_CR107", "doi-asserted-by": "publisher", "first-page": "2303", "DOI": "10.1182/blood-2002-06-1767", "volume": "100", "author": "J.D. Rizzo", "year": "2002", "unstructured": "Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Gordon MS, Gordon MS (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100: 2303\u20132320", "journal-title": "Blood"}, {"key": "16_CR108", "doi-asserted-by": "publisher", "first-page": "11609", "DOI": "10.1073/pnas.97.21.11609", "volume": "97", "author": "F.T. Ruschitzka", "year": "2000", "unstructured": "Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K, Kelm M, Noll G, R\u00fclicke T, Shaw S, Lindberg RLP, Rodenwald B, Lutz H, Bauer C, L\u00fcscher TF, Gassmann M (2000) Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 97: 11609\u201311613", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "16_CR109", "doi-asserted-by": "publisher", "first-page": "1442", "DOI": "10.1021/ac00104a022", "volume": "67", "author": "R.S. Rush", "year": "1995", "unstructured": "Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rohde MF, Katta V (1995) Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 67: 1442\u20131452", "journal-title": "Anal Chem"}, {"key": "16_CR110", "doi-asserted-by": "publisher", "first-page": "53", "DOI": "10.1111/j.1365-2796.1990.tb00192.x", "volume": "228", "author": "T. Salmonson", "year": "1990", "unstructured": "Salmonson T, Danielson BG, Grahnen A, Wikstrom B (1990b) Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. J Intern Med 228: 53\u201357", "journal-title": "J Intern Med"}, {"key": "16_CR111", "doi-asserted-by": "crossref", "first-page": "709", "DOI": "10.1111/j.1365-2125.1990.tb03692.x", "volume": "29", "author": "T. Salmonson", "year": "1990", "unstructured": "Salmonson T, Danielson BG, Wikstr\u00f6m B (1990a) The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 29: 709\u2013713", "journal-title": "Br J Clin Pharmacol"}, {"key": "16_CR112", "doi-asserted-by": "publisher", "first-page": "1775", "DOI": "10.1271/bbb.64.1775", "volume": "64", "author": "R. Sasaki", "year": "2000", "unstructured": "Sasaki R, Masuda S, Nagao M (2000) Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 64: 1775\u20131793", "journal-title": "Biosci Biotechnol Biochem"}, {"key": "16_CR113", "first-page": "237", "volume": "57", "author": "A. Sikole", "year": "2002", "unstructured": "Sikole A, Spasovski G, Zafirov D, Polenakovic M (2002) Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 57: 237\u2013245", "journal-title": "Clin Nephrol"}, {"key": "16_CR114", "doi-asserted-by": "publisher", "first-page": "3626", "DOI": "10.1182/blood.V98.13.3626", "volume": "98", "author": "V. Skibeli", "year": "2001", "unstructured": "Skibeli V, Nissen-Lie G, Torjesen P (2001) Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98: 3626\u20133634", "journal-title": "Blood"}, {"key": "16_CR115", "doi-asserted-by": "publisher", "first-page": "237", "DOI": "10.1016/S1387-2656(04)10008-2", "volume": "10", "author": "R. Smalling", "year": "2004", "unstructured": "Smalling R, Foote M, Molineux G, Swanson SJ, Elliott S (2004) Drug-induced and antibody-mediated pure red cell aplasia: A review of literature and current knowledge. Biotechnol Annu Rev 10: 237\u2013250", "journal-title": "Biotechnol Annu Rev"}, {"key": "16_CR116", "doi-asserted-by": "publisher", "first-page": "538", "DOI": "10.1016/S0008-6363(03)00468-1", "volume": "59", "author": "K.J. Smith", "year": "2003", "unstructured": "Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59: 538\u2013548", "journal-title": "Cardiovasc Res"}, {"key": "16_CR117", "first-page": "303", "volume": "1", "author": "B. Sowade", "year": "1998", "unstructured": "Sowade B, Sowade O, M\u00f6cks J, Franke W, Warnke H (1998) The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1: 303\u2013314", "journal-title": "Int J Mol Med"}, {"key": "16_CR118", "doi-asserted-by": "publisher", "first-page": "399", "DOI": "10.1159/000186598", "volume": "59", "author": "F. Stockenhuber", "year": "1991", "unstructured": "Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, Meisl TF, Balcke P (1991) Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 59: 399\u2013402", "journal-title": "Nephron"}, {"key": "16_CR119", "doi-asserted-by": "publisher", "first-page": "79", "DOI": "10.1046/j.1365-2141.1998.00521.x", "volume": "100", "author": "P.L. Storring", "year": "1998", "unstructured": "Storring PL, Tiplady RJ, Gaines DR, Stenning BE, Lamikanra A, Rafferty B, Lee J (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100: 79\u201389", "journal-title": "Br J Haematol"}, {"key": "16_CR120", "doi-asserted-by": "publisher", "first-page": "567", "DOI": "10.1080/028418698430278", "volume": "37", "author": "R.M. Sutherland", "year": "1998", "unstructured": "Sutherland RM (1998) Tumor hypoxia and gene expression \u2014 implications for malignant progression and therapy. Acta Oncol 37: 567\u2013574", "journal-title": "Acta Oncol"}, {"key": "16_CR121", "doi-asserted-by": "publisher", "first-page": "1184", "DOI": "10.1073/pnas.95.3.1184", "volume": "95", "author": "A.J. Sytkowski", "year": "1998", "unstructured": "Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S (1998) Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 95: 1184\u20131188", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "16_CR122", "doi-asserted-by": "publisher", "first-page": "5631", "DOI": "10.1074/jbc.270.10.5631", "volume": "270", "author": "T. Tauchi", "year": "1995", "unstructured": "Tauchi T, Feng GS, Shen R, Hoatlin M, Bagby GC Jr, Kabat D, Lu L, Broxmeyer HE (1995) Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem 270: 5631\u20135635", "journal-title": "J Biol Chem"}, {"key": "16_CR123", "first-page": "3339", "volume": "50", "author": "B.A. Teicher", "year": "1990", "unstructured": "Teicher BA, Holden SA, al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50: 3339\u20133344", "journal-title": "Cancer Res"}, {"issue": "[Suppl 8]", "key": "16_CR124", "doi-asserted-by": "publisher", "first-page": "60", "DOI": "10.1016/S0093-7754(01)90215-5", "volume": "28", "author": "G. Thomas", "year": "2001", "unstructured": "Thomas G (2001) The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 28 [Suppl 8]: 60\u201365", "journal-title": "Semin Oncol"}, {"key": "16_CR125", "doi-asserted-by": "publisher", "first-page": "5646", "DOI": "10.1021/bi00415a038", "volume": "27", "author": "E. Tsuda", "year": "1988", "unstructured": "Tsuda E, Goto M, Murakami A, Akai K, Ueda M, Kawanishi G, Takahashi N, Sasaki R, Chiba H, Ishihara H, et al (1988) Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry 27: 5646\u20135654", "journal-title": "Biochemistry"}, {"key": "16_CR126", "doi-asserted-by": "publisher", "first-page": "4457", "DOI": "10.1182/blood-2003-08-2713", "volume": "103", "author": "E. Akker van den", "year": "2004", "unstructured": "van den Akker E, van Dijk T, Parren-van Amelsvoort M, Grossmann KS, Schaeper U, Toney-Earley K, Waltz SE, Lowenberg B, von Lindern M (2004) Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. Blood 103: 4457\u20134465", "journal-title": "Blood"}, {"key": "16_CR127", "doi-asserted-by": "crossref", "first-page": "1211", "DOI": "10.1093/jnci/94.16.1211", "volume": "94", "author": "J. Vansteenkiste", "year": "2002", "unstructured": "Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211\u20131220", "journal-title": "J Natl Cancer Inst"}, {"key": "16_CR128", "doi-asserted-by": "publisher", "first-page": "992", "DOI": "10.1016/S0140-6736(04)15802-9", "volume": "363", "author": "P. Vaupel", "year": "2004", "unstructured": "Vaupel P, Mayer A (2004) Erythropoietin to treat anaemia in patients with head and neck cancer. The Lancet 363: 992", "journal-title": "The Lancet"}, {"key": "16_CR129", "first-page": "7634", "volume": "63", "author": "P. Vaupel", "year": "2003", "unstructured": "Vaupel P, Mayer A, Briest S, H\u00f6ckel M (2003) Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 63: 7634\u20137637", "journal-title": "Cancer Res"}, {"key": "16_CR130", "doi-asserted-by": "publisher", "first-page": "760", "DOI": "10.1002/jps.2600840619", "volume": "84", "author": "P. Veng-Pedersen", "year": "1995", "unstructured": "Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS (1995) Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 84: 760\u2013767", "journal-title": "J Pharm Sci"}, {"key": "16_CR131", "doi-asserted-by": "publisher", "first-page": "217", "DOI": "10.1002/(SICI)1099-081X(199905)20:4<217::AID-BDD177>3.0.CO;2-6", "volume": "20", "author": "P. Veng-Pedersen", "year": "1999", "unstructured": "Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, Lowe LS (1999) A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 20: 217\u2013223", "journal-title": "Biopharm Drug Dispos"}, {"key": "16_CR132", "doi-asserted-by": "publisher", "first-page": "536", "DOI": "10.1182/blood.V97.2.536", "volume": "97", "author": "K. Wagner", "year": "2001", "unstructured": "Wagner K, Katschinski DM, Hasegawa J, Schumacher D, Meller B, Gembruch U, Schramm U, Jelkmann W, Gassmann M, Fandrey J (2001) Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97: 536\u2013542", "journal-title": "Blood"}, {"key": "16_CR133", "doi-asserted-by": "publisher", "first-page": "600", "DOI": "10.1182/blood-2004-03-1216", "volume": "105", "author": "P. Walrafen", "year": "2005", "unstructured": "Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P (2005) Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105: 600\u2013608", "journal-title": "Blood"}, {"key": "16_CR134", "doi-asserted-by": "publisher", "first-page": "1116", "DOI": "10.1038/15104", "volume": "17", "author": "S. Weikert", "year": "1999", "unstructured": "Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M, Lofgren J, Mehta S, Chisholm V, Modi N, Eppler S, Carroll K, Chamow S, Peers D, Berman P, Krummen L (1999) Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nature Biotechnol 17: 1116\u20131121", "journal-title": "Nature Biotechnol"}, {"key": "16_CR135", "doi-asserted-by": "publisher", "first-page": "121", "DOI": "10.1111/j.1365-2141.1990.tb07846.x", "volume": "76", "author": "L. Wide", "year": "1990", "unstructured": "Wide L, Bengtsson C (1990) Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 76: 121\u2013127", "journal-title": "Br J Haematol"}, {"key": "16_CR136", "doi-asserted-by": "crossref", "first-page": "140", "DOI": "10.1152/jappl.1996.80.1.140", "volume": "80", "author": "J.A. Widness", "year": "1996", "unstructured": "Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS (1996) Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol 80: 140\u2013148", "journal-title": "J Appl Physiol"}, {"key": "16_CR137", "doi-asserted-by": "publisher", "first-page": "458", "DOI": "10.1126/science.273.5274.458", "volume": "273", "author": "N.C. Wrighton", "year": "1996", "unstructured": "Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273: 458\u2013464", "journal-title": "Science"}, {"key": "16_CR138", "doi-asserted-by": "publisher", "first-page": "129", "DOI": "10.1021/bp0101334", "volume": "18", "author": "M. Yang", "year": "2002", "unstructured": "Yang M, Butler M (2002) Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog 18: 129\u2013138", "journal-title": "Biotechnol Prog"}, {"key": "16_CR139", "doi-asserted-by": "crossref", "first-page": "6372", "DOI": "10.4049/jimmunol.165.11.6372", "volume": "165", "author": "CH Yen", "year": "2000", "unstructured": "Yen CH, Yang YC, Ruscetti SK, Kirken RA, Dai RM, Li CC (2000) Involvement of the ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-type cytokine receptors of IL-9, IL-2, and erythropoietin. J Immunol 165: 6372-6380", "journal-title": "J Immunol"}, {"key": "16_CR140", "first-page": "87", "volume": "85", "author": "T. Yi", "year": "1995", "unstructured": "Yi T, Zhang J, Miura O, Ihle JN (1995) Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. Blood 85: 87\u201395", "journal-title": "Blood"}, {"key": "16_CR141", "first-page": "227", "volume": "96", "author": "W.H. Yoon", "year": "1997", "unstructured": "Yoon WH, Park SJ, Kim IC, Lee MG (1997) Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 96: 227\u2013240", "journal-title": "Res Commun Mol Pathol Pharmacol"}, {"key": "16_CR142", "doi-asserted-by": "publisher", "first-page": "536", "DOI": "10.2165/00003495-199549040-00004", "volume": "49", "author": "P. Zachee", "year": "1995", "unstructured": "Zachee P (1995) Controversies in selection of epoetin dosages. Issues and answers. Drugs 49: 536\u2013547", "journal-title": "Drugs"}, {"key": "16_CR143", "doi-asserted-by": "publisher", "first-page": "133S", "DOI": "10.1592/phco.22.14.133S.33396", "volume": "22", "author": "W.C. Zamboni", "year": "2002", "unstructured": "Zamboni WC, Stewart CE (2002) An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy 22: 133S\u2013140S", "journal-title": "Pharmacotherapy"}], "container-title": ["Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-211-69459-6_16", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 14]], "date-time": "2019-03-14T11:19:46Z", "timestamp": 1552562386000}, "score": 27.586258, "issued": {"date-parts": [[2008]]}, "ISBN": ["9783211252239", "9783211694596"], "references-count": 143, "URL": "http://dx.doi.org/10.1007/978-3-211-69459-6_16", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T21:05:11Z", "timestamp": 1574456711874}, "publisher-location": "Vienna", "reference-count": 88, "publisher": "Springer Vienna", "isbn-type": [{"value": "9783709176603", "type": "print"}, {"value": "9783709176580", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2002]]}, "DOI": "10.1007/978-3-7091-7658-0_11", "type": "book-chapter", "created": {"date-parts": [[2012, 2, 29]], "date-time": "2012-02-29T01:46:31Z", "timestamp": 1330479991000}, "page": "203-221", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (rhEPO)"], "prefix": "10.1007", "author": [{"given": "Wolfgang", "family": "Jelkmann", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "11_CR1", "doi-asserted-by": "publisher", "first-page": "349", "DOI": "10.1146/annurev.me.41.020190.002025", "volume": "41", "author": "JW Adamson", "year": "1990", "unstructured": "Adamson JW, Eschbach JW (1990) Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 41: 349\u2013360", "journal-title": "Annu Rev Med"}, {"key": "11_CR2", "doi-asserted-by": "publisher", "first-page": "5978", "DOI": "10.1073/pnas.87.15.5978", "volume": "87", "author": "A Anagnostou", "year": "1990", "unstructured": "Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 5978\u20135982", "journal-title": "Proc Natl Acad Sci USA"}, {"issue": "12", "key": "11_CR3", "doi-asserted-by": "publisher", "first-page": "80", "DOI": "10.1093/ndt/14.suppl_2.80", "volume": "14", "author": "FP Barbone", "year": "1999", "unstructured": "Barbone FP, Johnson DL, Farrell FX, Collins A, Middleton SA, McMahon FJ, Tullai J, Jolliffe LK (1999) New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 14 (Supp12): 80\u201384", "journal-title": "Nephrol Dial Transplant"}, {"key": "11_CR4", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1007/BF01737420", "volume": "68", "author": "G Barosi", "year": "1994", "unstructured": "Barosi G (1994) Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 68: 215\u2013223", "journal-title": "Ann Hematol"}, {"key": "11_CR5", "first-page": "2010", "volume": "82", "author": "Y Beguin", "year": "1993", "unstructured": "Beguin Y, Loo M, R\u2019Zik S, Sautois B, Lejeune F, Rorive G, Fillet G (1993) Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82: 2010\u20132016", "journal-title": "Blood"}, {"key": "11_CR6", "doi-asserted-by": "publisher", "first-page": "125", "DOI": "10.1111/j.1365-2796.1991.tb00319.x", "volume": "229", "author": "B Berglund", "year": "1991", "unstructured": "Berglund B, Ekblom B (1991) Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 229: 125\u2013130", "journal-title": "J Intern Med"}, {"key": "11_CR7", "author": "H Bergrem", "first-page": "265", "year": "1993", "unstructured": "Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M (1993) A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C, Koch KM, Scigalla P, Wieczorek L (eds) Erythropoietin, molecular physiology and clinical applications. Marcel Dekker, New York Basel Hong Kong, pp 265\u2013273", "volume-title": "Erythropoietin, molecular physiology and clinical applications"}, {"key": "11_CR8", "doi-asserted-by": "publisher", "first-page": "253", "DOI": "10.1046/j.1523-1755.1999.00531.x", "volume": "56", "author": "JS Berns", "year": "1999", "unstructured": "Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC (1999) Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 56: 253\u2013260", "journal-title": "Kidney Int"}, {"key": "11_CR9", "doi-asserted-by": "publisher", "first-page": "584", "DOI": "10.1056/NEJM199808273390903", "volume": "339", "author": "A Besarab", "year": "1998", "unstructured": "Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584\u2013590", "journal-title": "N Engl J Med"}, {"key": "11_CR10", "first-page": "499", "volume": "34", "author": "J Brockm\u00f6ller", "year": "1992", "unstructured": "Brockm\u00f6ller J, K\u00f6chling J, Weber W, Looby M, Roots I, Neumayer H-H (1992) The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 34: 499\u2013508", "journal-title": "Br J Clin Pharmacol"}, {"key": "11_CR11", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1016/S1357-4310(00)01677-4", "volume": "6", "author": "JM Brown", "year": "2000", "unstructured": "Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6: 157\u2013162", "journal-title": "Mol Med Today"}, {"key": "11_CR12", "doi-asserted-by": "publisher", "first-page": "412", "DOI": "10.1002/ajh.2830420428", "volume": "42", "author": "A Buchbinder", "year": "1993", "unstructured": "Buchbinder A, Adler H, Ballard H (1993) An unusual and unreported toxicity to erythropoietin. Am J Hematol 42: 412\u2013413", "journal-title": "Am J Hematol"}, {"key": "11_CR13", "doi-asserted-by": "publisher", "first-page": "313", "DOI": "10.1006/phrs.1999.0593", "volume": "41", "author": "G Castelli", "year": "2000", "unstructured": "Castelli G, Famularo A, Semino C, Machi AM, Ceci A, Cannella G, Melioli G (2000) Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol Res 41: 313\u2013318", "journal-title": "Pharmacol Res"}, {"key": "11_CR14", "first-page": "4446", "volume": "86", "author": "M Cazzola", "year": "1995", "unstructured": "Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller ZL, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin\u2019s lymphoma: dose finding and identification of predictors of response. Blood 86: 4446\u20134453", "journal-title": "Blood"}, {"key": "11_CR15", "doi-asserted-by": "publisher", "first-page": "412", "DOI": "10.1016/S0009-9236(98)90072-8", "volume": "64", "author": "WK Cheung", "year": "1998", "unstructured": "Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC (1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64: 412\u2013423", "journal-title": "Clin Pharmacol Ther"}, {"key": "11_CR16", "doi-asserted-by": "publisher", "first-page": "505", "DOI": "10.1159/000187555", "volume": "65", "author": "M Cirillo", "year": "1993", "unstructured": "Cirillo M, Capasso G, DeSanto NG (1993) Relationship between hematocrit and blood pressure: implications for primary hypertension. Nephron 65: 505\u2013510", "journal-title": "Nephron"}, {"key": "11_CR17", "first-page": "F939", "volume": "263", "author": "GA Coles", "year": "1992", "unstructured": "Coles GA, Liberek T, Davies ME, Robinson M, Jones J, Thomas G, Davies M, MacDougall IC, Williams JD (1992) Estimation of erythropoietin secretion rate in normal and uremic subjects. Am J Physiol 263: F939 - F944", "journal-title": "Am J Physiol"}, {"key": "11_CR18", "author": "PM Cotes", "first-page": "70", "year": "1989", "unstructured": "Cotes PM, Pippard MJ, Reid CD, Winearls CG, Oliver DO, Royston JP (1989) Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 70: 113\u2013137", "volume-title": "Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO)"}, {"key": "11_CR19", "doi-asserted-by": "publisher", "first-page": "265", "DOI": "10.1111/j.1365-2141.1987.tb06852.x", "volume": "65", "author": "EN Dessypris", "year": "1987", "unstructured": "Dessypris EN, Gleaton JH, Armstrong OL (1987) Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol 65: 265\u2013269", "journal-title": "Br J Haematol"}, {"key": "11_CR20", "author": "CJ Dunn", "first-page": "51", "year": "1996", "unstructured": "Dunn CJ, Markham A (1996) Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs 51: 299\u2013318", "volume-title": "Epoetin beta"}, {"issue": "4", "key": "11_CR21", "first-page": "4", "volume": "27", "author": "J Dunst", "year": "2000", "unstructured": "Dunst J (2000) Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 27 (Suppl 4): 4\u20138", "journal-title": "Semin Oncol"}, {"issue": "243", "key": "11_CR22", "first-page": "1", "volume": "56", "author": "JC Egrie", "year": "1997", "unstructured": "Egrie JC, Dwyer E, Lykos M, Hitz A, Browne JK (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity compared to recombinant human erythropoietin (rHuEPO). Blood 90 (Suppl 1 ): 56a (Abstr 243)", "journal-title": "Blood 90 (Suppl"}, {"key": "11_CR23", "doi-asserted-by": "publisher", "first-page": "291", "DOI": "10.1056/NEJM198408023110504", "volume": "311", "author": "SH Embury", "year": "1984", "unstructured": "Embury SH, Garcia JF, Mohandas N, Pennathur DR, Clark MR (1984) Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. N Engl J Med 311: 291\u2013295", "journal-title": "N Engl J Med"}, {"key": "11_CR24", "author": "JW Eschbach", "first-page": "316", "year": "1987", "unstructured": "Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73\u201378", "volume-title": "Correction of the anemia of end-stage renal disease with recombinant human erythropoietin"}, {"key": "11_CR25", "first-page": "81", "volume": "5", "author": "T Fjornes", "year": "1998", "unstructured": "Fjornes T, Wiedemann GJ, Sack K, Jelkmann W (1998) Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy. Oncol Rep 5: 81\u201386", "journal-title": "Oncol Rep"}, {"key": "11_CR26", "doi-asserted-by": "publisher", "first-page": "557", "DOI": "10.1038/clpt.1990.76", "volume": "47", "author": "KK Flaharty", "year": "1990", "unstructured": "Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH (1990) Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47: 557\u2013564", "journal-title": "Clin Pharmacol Ther"}, {"key": "11_CR27", "doi-asserted-by": "publisher", "first-page": "636", "DOI": "10.1159/000187578", "volume": "65", "author": "JE Garcia", "year": "1993", "unstructured": "Garcia JE, Senent C, Pascual C, Fernandez G, Perez CC, Diaz TR, Gomez E, Sierra T (1993) Anaphylactic reaction to recombinant human erythropoietin. Nephron 65: 636\u2013637", "journal-title": "Nephron"}, {"key": "11_CR28", "doi-asserted-by": "publisher", "first-page": "702", "DOI": "10.1038/clpt.1991.210", "volume": "50", "author": "CE Halstenson", "year": "1991", "unstructured": "Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50: 702\u2013712", "journal-title": "Clin Pharmacol Ther"}, {"key": "11_CR29", "doi-asserted-by": "publisher", "first-page": "253", "DOI": "10.1016/S1045-1056(05)80044-2", "volume": "20", "author": "T Hayakawa", "year": "1992", "unstructured": "Hayakawa T, Wada M, Mizuno K, Abe S, Miyashita M, Ueda M (1992) In vivo biological activities of recombinant human erythropoietin analogues produced by CHO cells, BHK cells and C127 cells. Biologicals 20: 253\u2013257", "journal-title": "Biologicals"}, {"key": "11_CR30", "doi-asserted-by": "crossref", "first-page": "246", "DOI": "10.1093/oxfordjournals.ndt.a027248", "volume": "11", "author": "WH Horl", "year": "1996", "unstructured": "Horl WH, Cavill I, MacDougall IC, Schaefer RM, Sunder-Plassmann G (1996) How to diagnose and correct iron deficiency during r-huEPO therapy \u2014 a consensus report. Nephrol Dial Transplant 11: 246\u2013250", "journal-title": "Nephrol Dial Transplant"}, {"key": "11_CR31", "doi-asserted-by": "publisher", "first-page": "297", "DOI": "10.1016/S1387-2656(08)70055-3", "volume": "1", "author": "N Inoue", "year": "1995", "unstructured": "Inoue N, Takeuchi M, Ohashi H, Suzuki T (1995) The production of recombinant human erythropoietin. Biotechnol Annu Rev 1: 297\u2013313", "journal-title": "Biotechnol Annu Rev"}, {"key": "11_CR32", "doi-asserted-by": "publisher", "first-page": "401", "DOI": "10.1016/0002-9343(93)90151-E", "volume": "94", "author": "T Ishimitsu", "year": "1993", "unstructured": "Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S (1993) Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 94: 401\u2013406", "journal-title": "Am J Med"}, {"key": "11_CR33", "doi-asserted-by": "crossref", "first-page": "449", "DOI": "10.1152/physrev.1992.72.2.449", "volume": "72", "author": "W Jelkmann", "year": "1992", "unstructured": "Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72: 449\u2013489", "journal-title": "Physiol Rev"}, {"key": "11_CR34", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.2174/1389201003379068", "volume": "1", "author": "W Jelkmann", "year": "2000", "unstructured": "Jelkmann W (2000) Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharmaceut Biotechnol 1: 11\u201331", "journal-title": "Curr Pharmaceut Biotechnol"}, {"key": "11_CR35", "author": "W Jelkmann", "year": "1989", "unstructured": "Jelkmann W, Gross A (1989) Erythropoietin. Springer, Berlin Heidelberg New York", "volume-title": "Erythropoietin", "DOI": "10.1007/978-3-642-83745-6", "doi-asserted-by": "publisher"}, {"key": "11_CR36", "first-page": "177", "volume": "5", "author": "JD Jensen", "year": "1994", "unstructured": "Jensen JD, Madsen JK, Jensen LW, Pedersen EB (1994) Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 5: 177\u2013185", "journal-title": "J Am Soc Nephrol"}, {"key": "11_CR37", "doi-asserted-by": "publisher", "first-page": "393", "DOI": "10.1159/000186955", "volume": "61", "author": "D Kampf", "year": "1992", "unstructured": "Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M (1992) Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 61: 393\u2013398", "journal-title": "Nephron"}, {"key": "11_CR38", "first-page": "266", "volume": "138", "author": "K Kayser", "year": "1992", "unstructured": "Kayser K, Gabius HJ (1992) Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentralbi Pathol 138: 266\u2013270", "journal-title": "Zentralbi Pathol"}, {"key": "11_CR39", "doi-asserted-by": "crossref", "first-page": "345", "DOI": "10.1093/oxfordjournals.ndt.a091888", "volume": "4", "author": "J Kindler", "year": "1989", "unstructured": "Kindler J, Eckardt KU, Ehmer B, Jandeleit K, Kurtz A, Schreiber A, Scigalla P, Sieberth HG (1989) Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 4: 345\u2013349", "journal-title": "Nephrol Dial Transplant"}, {"key": "11_CR40", "doi-asserted-by": "publisher", "first-page": "729", "DOI": "10.1016/0092-8674(95)90351-8", "volume": "80", "author": "U Klingm\u00fcller", "year": "1995", "unstructured": "Klingm\u00fcller U, Lorenz U, Cantley LC, Neel BG, Lodish HF (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80: 729\u2013738", "journal-title": "Cell"}, {"key": "11_CR41", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1016/0167-7799(89)90095-4", "volume": "7", "author": "M Konrad", "year": "1989", "unstructured": "Konrad M (1989) Immunogenicity of proteins administered to humans for therapeutic purposes. Tibtech 7: 175\u2013179", "journal-title": "Tibtech"}, {"key": "11_CR42", "doi-asserted-by": "publisher", "first-page": "149", "DOI": "10.1016/S0009-8981(99)00213-2", "volume": "292", "author": "W Korte", "year": "2000", "unstructured": "Korte W, Cogliatti SB, Jung K, Riesen W (2000) Mild renal dysfunction is sufficient to induce erythropoietin deficiency in patients with unexplained anaemia. Clin Chim Acta 292: 149\u2013154", "journal-title": "Clin Chim Acta"}, {"key": "11_CR43", "doi-asserted-by": "publisher", "first-page": "378", "DOI": "10.1126/science.2326648", "volume": "248", "author": "MJ Koury", "year": "1990", "unstructured": "Koury MJ, Bondurant MC (1990) Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248: 378\u2013381", "journal-title": "Science"}, {"key": "11_CR44", "doi-asserted-by": "publisher", "first-page": "649", "DOI": "10.1111/j.1432-1033.1992.tb17466.x", "volume": "210", "author": "MJ Koury", "year": "1992", "unstructured": "Koury MJ, Bondurant MC (1992) The molecular mechanism of erythropoietin action. Eur J Biochem 210: 649\u2013663", "journal-title": "Eur J Biochem"}, {"key": "11_CR45", "first-page": "419", "volume": "77", "author": "SB Krantz", "year": "1991", "unstructured": "Krantz SB (1991) Erythropoietin. Blood 77: 419\u2013434", "journal-title": "Erythropoietin. Blood"}, {"key": "11_CR46", "first-page": "635", "volume": "405", "author": "F Lasne", "year": "2000", "unstructured": "Lasne F, de Ceaurriz J (2000) Recombinant erythropoietin in urine. Nature 405: 635", "journal-title": "Recombinant erythropoietin in urine. Nature"}, {"key": "11_CR47", "author": "VS Lim", "first-page": "110", "year": "1989", "unstructured": "Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J (1989) Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110: 108\u2013114", "volume-title": "Recombinant human erythropoietin treatment in pre-dialysis patients"}, {"key": "11_CR48", "doi-asserted-by": "publisher", "first-page": "464", "DOI": "10.1126/science.273.5274.464", "volume": "273", "author": "O Livnah", "year": "1996", "unstructured": "Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA (1996) Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273: 464\u2013471", "journal-title": "Science"}, {"key": "11_CR49", "first-page": "47", "volume": "33", "author": "SF Lui", "year": "1990", "unstructured": "Lui SF, Chung WW, Leung CB, Chan K, Lai KN (1990) Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 33: 47\u201351", "journal-title": "Clin Nephrol"}, {"key": "11_CR50", "first-page": "375", "volume": "20", "author": "IC Macdougall", "year": "2000", "unstructured": "MacDougall IC (2000) Novel erythropoiesis stimulating protein. Semin Nephrol 20: 375\u2013381", "journal-title": "Semin Nephrol"}, {"key": "11_CR51", "doi-asserted-by": "publisher", "first-page": "425", "DOI": "10.1016/S0140-6736(89)90014-7", "volume": "1", "author": "IC Macdougall", "year": "1989", "unstructured": "MacDougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD (1989) Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1: 425\u2013427", "journal-title": "Lancet"}, {"key": "11_CR52", "first-page": "2392", "volume": "10", "author": "IC Macdougall", "year": "1999", "unstructured": "MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392\u20132395", "journal-title": "J Am Soc Nephrol"}, {"key": "11_CR53", "first-page": "1", "volume": "70", "author": "S Masuda", "year": "1999", "unstructured": "Masuda S, Nagao M, Sasaki R (1999) Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 70: 1\u20136", "journal-title": "Int J Hematol"}, {"key": "11_CR54", "first-page": "1718", "volume": "76", "author": "FG Mcmahon", "year": "1990", "unstructured": "McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL (1990) Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76: 1718\u20131722", "journal-title": "Blood"}, {"key": "11_CR55", "first-page": "84", "volume": "21", "author": "R Montagnac", "year": "1992", "unstructured": "Montagnac R, Boffa GA, Schillinger F, Guillaumie J (1992) Sensibilisation \u00e0 l\u2019\u00e9rythropo\u00ef\u00e9tine humaine recombinante chez une h\u00e9modialys\u00e9e. Presse Med 21: 84\u201385", "journal-title": "Presse Med"}, {"key": "11_CR56", "author": "F Moreno", "first-page": "11", "year": "2000", "unstructured": "Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F (2000) Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11: 335\u2013342", "volume-title": "Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients"}, {"key": "11_CR57", "doi-asserted-by": "publisher", "first-page": "343", "DOI": "10.1016/1357-4310(96)81800-4", "volume": "2", "author": "N Naffakh", "year": "1996", "unstructured": "Naffakh N, Danos O (1996) Gene transfer for erythropoiesis enhancement. Mol Med Today 2: 343\u2013348", "journal-title": "Mol Med Today"}, {"key": "11_CR58", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1111/j.1600-0773.1990.tb00710.x", "volume": "66", "author": "OJ Nielsen", "year": "1990", "unstructured": "Nielsen OJ (1990) Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol 66: 83\u201386", "journal-title": "Pharmacol Toxicol"}, {"issue": "1", "key": "11_CR59", "first-page": "S19", "volume": "15", "author": "MR Nowrousian", "year": "1998", "unstructured": "Nowrousian MR (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15 (Suppl 1): S19 \u2014 S28", "journal-title": "Med Oncol"}, {"key": "11_CR60", "author": "H Pagel", "year": "1992", "unstructured": "Pagel H, Weiss C, Jelkmann W (1992) Pathophysiology and pharmacology of erythropoietin. Springer, Berlin", "volume-title": "Pathophysiology and pharmacology of erythropoietin", "DOI": "10.1007/978-3-642-77074-6", "doi-asserted-by": "publisher"}, {"key": "11_CR61", "first-page": "523", "volume": "335", "author": "R Peces", "year": "1996", "unstructured": "Peces R, de la Torre M, Alcazar R, Urra JM (1996) Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335: 523\u2013524", "journal-title": "Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med"}, {"key": "11_CR62", "first-page": "331", "volume": "47", "author": "SS Prabhakar", "year": "1997", "unstructured": "Prabhakar SS, Muhlfelder T (1997) Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 47: 331\u2013335", "journal-title": "Clin Nephrol"}, {"key": "11_CR63", "doi-asserted-by": "publisher", "first-page": "12156", "DOI": "10.1073/pnas.96.21.12156", "volume": "96", "author": "SA Qureshi", "year": "1999", "unstructured": "Qureshi SA, Kim RM, Konteatis Z, Biazzo DE, Motamedi H, Rodrigues R, Boice JA, Calaycay JR, Bednarek MA, Griffin P, Gao YD, Chapman K, Mark DF (1999) Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 96: 12156\u201312161", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "11_CR64", "doi-asserted-by": "publisher", "first-page": "948", "DOI": "10.1002/(SICI)1096-9888(199709)32:9<948::AID-JMS551>3.0.CO;2-C", "volume": "32", "author": "NH Rahbek", "year": "1997", "unstructured": "Rahbek NH, Roepstorff P, Reischl H, Wozny M, Koll H, Haselbeck A (1997) Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 32: 948\u2013958", "journal-title": "J Mass Spectrom"}, {"key": "11_CR65", "first-page": "17156", "volume": "262", "author": "MA Recny", "year": "1987", "unstructured": "Recny MA, Scoble HA, Kim Y (1987) Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 262: 17156\u201317163", "journal-title": "J Biol Chem"}, {"key": "11_CR66", "doi-asserted-by": "publisher", "first-page": "1881", "DOI": "10.1089/hum.1997.8.16-1881", "volume": "8", "author": "C Rinsch", "year": "1997", "unstructured": "Rinsch C, Regulier E, Deglon N, Dalle B, Beuzard Y, Aebischer P (1997) A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 8: 1881\u20131889", "journal-title": "Hum Gene Ther"}, {"key": "11_CR67", "first-page": "11609", "volume": "97", "author": "FT Ruschitzka", "year": "2000", "unstructured": "Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K, Kelm M, Noll G, R\u00fclicke T, Shaw S, Lindberg RLP, Rodenwald B, Lutz H, Bauer C, L\u00f6scher TF, Gassmann M (2000) Nitric oxide prevents cardiovascular disease and determines survival in polygiobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 97: 11609\u201311613", "journal-title": "Nitric oxide prevents cardiovascular disease and determines survival in polygiobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA"}, {"key": "11_CR68", "doi-asserted-by": "publisher", "first-page": "1442", "DOI": "10.1021/ac00104a022", "volume": "67", "author": "RS Rush", "year": "1995", "unstructured": "Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rohde MF, Katta V (1995) Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 67: 1442\u20131452", "journal-title": "Anal Chem"}, {"key": "11_CR69", "doi-asserted-by": "publisher", "first-page": "26", "DOI": "10.1006/bbrc.1998.9748", "volume": "253", "author": "Y Sadamoto", "year": "1998", "unstructured": "Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R (1998) Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253: 26\u201332", "journal-title": "Biochem Biophys Res Commun"}, {"key": "11_CR70", "doi-asserted-by": "publisher", "first-page": "4635", "DOI": "10.1073/pnas.95.8.4635", "volume": "95", "author": "M Sakanaka", "year": "1998", "unstructured": "Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95: 4635\u20134640", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "11_CR71", "doi-asserted-by": "crossref", "first-page": "709", "DOI": "10.1111/j.1365-2125.1990.tb03692.x", "volume": "29", "author": "T Salmonson", "year": "1990", "unstructured": "Salmonson T, Danielson BG, Wikstr\u00f6m B (1990a) The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 29: 709\u2013713", "journal-title": "Br J Clin Pharmacol"}, {"key": "11_CR72", "doi-asserted-by": "publisher", "first-page": "53", "DOI": "10.1111/j.1365-2796.1990.tb00192.x", "volume": "228", "author": "T Salmonson", "year": "1990", "unstructured": "Salmonson T, Danielson BG, Grahnen A, Wikstrom B (1990b) Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. J Intern Med 228: 53\u201357", "journal-title": "J Intern Med"}, {"key": "11_CR73", "author": "D Silverberg", "first-page": "80", "year": "1998", "unstructured": "Silverberg D, Blum M, Peer G, Iaina A (1998) Anemia during the predialysis period: A key to cardiac damage in renal failure. Nephron 80: 1\u20135", "volume-title": "Anemia during the predialysis period"}, {"key": "11_CR74", "first-page": "303", "volume": "1", "author": "B Sowade", "year": "1998", "unstructured": "Sowade B, Sowade O, M\u00f6cks J, Franke W, Warnke H (1998) The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1: 303\u2013314", "journal-title": "Int J Mol Med"}, {"key": "11_CR75", "doi-asserted-by": "publisher", "first-page": "399", "DOI": "10.1159/000186598", "volume": "59", "author": "F Stockenhuber", "year": "1991", "unstructured": "Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, Meisl TF, Balcke P (1991) Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 59: 399\u2013402", "journal-title": "Nephron"}, {"key": "11_CR76", "doi-asserted-by": "publisher", "first-page": "79", "DOI": "10.1046/j.1365-2141.1998.00521.x", "volume": "100", "author": "PL Storring", "year": "1998", "unstructured": "Storring PL, Tiplady RJ, Gaines DR, Stenning BE, Lamikanra A, Rafferty B, Lee J (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100: 79\u201389", "journal-title": "Br J Haematol"}, {"key": "11_CR77", "doi-asserted-by": "publisher", "first-page": "567", "DOI": "10.1080/028418698430278", "volume": "37", "author": "RM Sutherland", "year": "1998", "unstructured": "Sutherland RM (1998) Tumor hypoxia and gene expression \u2014 implications for malignant progression and therapy. Acta Oncol 37: 567\u2013574", "journal-title": "Acta Oncol"}, {"key": "11_CR78", "doi-asserted-by": "publisher", "first-page": "1184", "DOI": "10.1073/pnas.95.3.1184", "volume": "95", "author": "AJ Sytkowski", "year": "1998", "unstructured": "Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S (1998) Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 95: 1184\u20131188", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "11_CR79", "first-page": "5631", "volume": "270", "author": "T Tauchi", "year": "1995", "unstructured": "Tauchi T, Feng GS, Shen R, Hoatlin M, Bagby-GC J, Kabat D, Lu L, Broxmeyer HE (1995) Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem 270: 5631\u20135635", "journal-title": "Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem"}, {"key": "11_CR80", "first-page": "848", "volume": "43", "author": "JM Urra", "year": "1997", "unstructured": "Urra JM, de-la-Torre M, Alcazar R, Peces R (1997) Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance. Clin Chem 43: 848\u2013849", "journal-title": "Clin Chem"}, {"key": "11_CR81", "doi-asserted-by": "publisher", "first-page": "536", "DOI": "10.1182/blood.V97.2.536", "volume": "97", "author": "K Wagner", "year": "2001", "unstructured": "Wagner K, Katschinski DM, Hasegawa J, Schumacher D, Metier B, Gembruch U, Schramm U, Jelkmann W, Gassmann M, Fandrey J (2001) Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice over-expressing erythropoietin. Blood 97: 536\u2013542", "journal-title": "Blood"}, {"key": "11_CR82", "doi-asserted-by": "publisher", "first-page": "1116", "DOI": "10.1038/15104", "volume": "17", "author": "S Weikert", "year": "1999", "unstructured": "Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M, Lofgren J, Mehta S, Chisholm V, Modi N, Eppler S, Carroll K, Chamow S, Peers D, Berman P, Krummen L (1999) Engineering chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 17: 1116\u20131121", "journal-title": "Nat Biotechnol"}, {"key": "11_CR83", "doi-asserted-by": "publisher", "first-page": "647", "DOI": "10.1046/j.1523-1755.2000.00211.x", "volume": "58", "author": "C Westenfelder", "year": "2000", "unstructured": "Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647\u2013657", "journal-title": "Kidney Int"}, {"key": "11_CR84", "doi-asserted-by": "publisher", "first-page": "121", "DOI": "10.1111/j.1365-2141.1990.tb07846.x", "volume": "76", "author": "L Wide", "year": "1990", "unstructured": "Wide L, Bengtsson C (1990) Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 76: 121\u2013127", "journal-title": "Br J Haematol"}, {"key": "11_CR85", "doi-asserted-by": "crossref", "first-page": "140", "DOI": "10.1152/jappl.1996.80.1.140", "volume": "80", "author": "JA Widness", "year": "1996", "unstructured": "Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS (1996) Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol 80: 140\u2013148", "journal-title": "J Appl Physiol"}, {"key": "11_CR86", "doi-asserted-by": "publisher", "first-page": "458", "DOI": "10.1126/science.273.5274.458", "volume": "273", "author": "NC Wrighton", "year": "1996", "unstructured": "Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273: 458\u2013464", "journal-title": "Science"}, {"key": "11_CR87", "first-page": "87", "volume": "85", "author": "T Yi", "year": "1995", "unstructured": "Yi T, Zhang J, Miura O, Ihle JN (1995) Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. Blood 85: 87\u201395", "journal-title": "Blood"}, {"key": "11_CR88", "doi-asserted-by": "publisher", "first-page": "536", "DOI": "10.2165/00003495-199549040-00004", "volume": "49", "author": "P Zachee", "year": "1995", "unstructured": "Zachee P (1995) Controversies in selection of epoetin dosages. Issues and answers. Drugs 49: 536\u2013547", "journal-title": "Drugs"}], "container-title": ["Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-7091-7658-0_11", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 4]], "date-time": "2019-11-04T10:40:11Z", "timestamp": 1572864011000}, "score": 27.586258, "issued": {"date-parts": [[2002]]}, "ISBN": ["9783709176603", "9783709176580"], "references-count": 88, "URL": "http://dx.doi.org/10.1007/978-3-7091-7658-0_11", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T16:59:08Z", "timestamp": 1574269148952}, "reference-count": 22, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3134, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2007, 2]]}, "DOI": "10.1177/0091270006296058", "type": "journal-article", "created": {"date-parts": [[2007, 1, 23]], "date-time": "2007-01-23T20:39:06Z", "timestamp": 1169584746000}, "page": "218-226", "source": "Crossref", "is-referenced-by-count": 161, "title": ["Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects"], "prefix": "10.1002", "volume": "47", "author": [{"given": "Dagmar", "family": "Kubitza", "sequence": "first", "affiliation": []}, {"given": "Michael", "family": "Becka", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Zuehlsdorf", "sequence": "additional", "affiliation": []}, {"given": "Wolfgang", "family": "Mueck", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2013, 3, 7]]}, "reference": [{"key": "10.1177/0091270006296058-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "867", "DOI": "10.7326/0003-4819-140-11-200406010-00007", "article-title": "Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial", "volume": "140", "author": "Buller", "year": "2004", "journal-title": "Ann Intern Med."}, {"key": "10.1177/0091270006296058-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "1512", "DOI": "10.1345/aph.1C025", "article-title": "Patient-specific factors predictive of warfarin dosage requirements", "volume": "36", "author": "Absher", "year": "2002", "journal-title": "Ann Pharmacother"}, {"key": "10.1177/0091270006296058-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "2049", "DOI": "10.1378/chest.127.6.2049", "article-title": "Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population", "volume": "127", "author": "Garcia", "year": "2005", "journal-title": "Chest"}, {"key": "10.1177/0091270006296058-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "1197", "DOI": "10.1016/S0140-6736(05)67483-1", "article-title": "Obesity", "volume": "366", "author": "Haslam", "year": "2005", "journal-title": "Lancet"}, {"key": "10.1177/0091270006296058-BIB5|cit5", "unstructured": "National Institute of Diabetes & Digestive & Kidney Disease Weight-control information network. Statistics related to overweight and obesity 2005 http://win.niddk.nih.gov/statistics/index.htm"}, {"key": "10.1177/0091270006296058-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "4", "DOI": "10.1136/bjsm.2004.011841", "article-title": "Obesity: a preventable risk factor for large joint osteoarthritis which may act through biomechanical factors", "volume": "39", "author": "Powell", "year": "2005", "journal-title": "Br J Sports Med."}, {"key": "10.1177/0091270006296058-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "290", "DOI": "10.1016/S0749-3797(03)00218-6", "article-title": "Relationships between body mass indices and surgical replacements of knee and hip joints", "volume": "25", "author": "Wendelboe", "year": "2003", "journal-title": "Am J Prev Med."}, {"key": "10.1177/0091270006296058-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "429S", "DOI": "10.1378/chest.126.3_suppl.429S", "article-title": "Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy", "volume": "126", "author": "Singer", "year": "2004", "journal-title": "Chest"}, {"key": "10.1177/0091270006296058-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "412", "DOI": "10.1016/j.clpt.2005.06.011", "article-title": "Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor", "volume": "78", "author": "Kubitza", "year": "2005", "journal-title": "Clin Pharmacol Ther."}, {"key": "10.1177/0091270006296058-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "873", "DOI": "10.1007/s00228-005-0043-5", "article-title": "Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects", "volume": "61", "author": "Kubitza", "year": "2005", "journal-title": "Eur J Clin Pharmacol."}, {"key": "10.1177/0091270006296058-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "2479", "DOI": "10.1111/j.1538-7836.2005.01602.x", "article-title": "BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study", "volume": "3", "author": "Turpie", "year": "2005", "journal-title": "J Thromb Haemost"}, {"key": "10.1177/0091270006296058-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "121", "DOI": "10.1111/j.1538-7836.2005.01657.x", "article-title": "Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement", "volume": "4", "author": "Eriksson", "year": "2006", "journal-title": "J Thromb Haemost"}, {"key": "10.1177/0091270006296058-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "2374", "DOI": "10.1161/CIRCULATIONAHA.106.642074", "article-title": "A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement", "volume": "114", "author": "Eriksson", "year": "2006", "journal-title": "Circulation"}, {"key": "10.1177/0091270006296058-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "891", "DOI": "10.1080/00498250500250493", "article-title": "Pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-in rats and dogs", "volume": "35", "author": "Weinz", "year": "2005", "journal-title": "Xenobiotica"}, {"key": "10.1177/0091270006296058-BIB15|cit15", "unstructured": "US Food and Drug Administration Center for Drug Evaluation and Research Bioavailability and bioequivalence studies for orally administered drug products-general considerations 2002 http://www.fda.gov/cder/guidance/3615fnl.htm"}, {"key": "10.1177/0091270006296058-BIB16|cit16", "first-page": "A2", "article-title": "Pharmacokinetic and pharmacodynamic analyses of rivaroxaban in patients undergoing orthopaedic surgery [abstract]", "volume": "35", "author": "Turpie", "year": "2006", "journal-title": "Pathophysiol Haemost Thromb"}, {"key": "10.1177/0091270006296058-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "981", "DOI": "10.1177/0091270006292127", "article-title": "Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin", "volume": "46", "author": "Kubitza", "year": "2006", "journal-title": "J Clin Pharmacol."}, {"key": "10.1177/0091270006296058-BIB18|cit18", "year": "2004", "volume-title": "Fragmin (dalteparin sodium injection) [prescribing information]"}, {"key": "10.1177/0091270006296058-BIB19|cit19", "year": "2005", "volume-title": "Lovenox (enoxaparin sodium injection) [prescribing information]"}, {"key": "10.1177/0091270006296058-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "100", "DOI": "10.1111/j.1538-7836.2004.01053.x", "article-title": "The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients", "volume": "3", "author": "Al Yaseen", "year": "2005", "journal-title": "J Thromb Haemost"}, {"key": "10.1177/0091270006296058-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "745", "DOI": "10.7326/0003-4819-141-10-200411160-00005", "article-title": "Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation", "volume": "141", "author": "Fang", "year": "2004", "journal-title": "Ann Intern Med."}, {"key": "10.1177/0091270006296058-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "204", "DOI": "10.1016/j.clpt.2003.10.001", "article-title": "Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin", "volume": "75", "author": "Kamali", "year": "2004", "journal-title": "Clin Pharmacol Ther."}], "container-title": ["The Journal of Clinical Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1177%2F0091270006296058", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1177/0091270006296058", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 4]], "date-time": "2018-08-04T21:50:54Z", "timestamp": 1533419454000}, "score": 27.57446, "issued": {"date-parts": [[2007, 2]]}, "references-count": 22, "journal-issue": {"published-print": {"date-parts": [[2007, 2]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1177/0091270006296058", "relation": {"cites": []}, "ISSN": ["0091-2700"], "issn-type": [{"value": "0091-2700", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:17:11Z", "timestamp": 1575530231668}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2005, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>BAY 59-7939 is a novel, oral, direct Factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. BAY 59-7939 compared favourably with enoxaparin in recent clinical trials of the prevention of venous thromboembolism following major orthopaedic surgery. Possible concomitant medications in patients receiving BAY 59-7939 for either the prevention or treatment of venous thromboembolism include non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen. This randomized, two-way crossover study was performed to investigate the influence of naproxen on the safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939 in 11 healthy male subjects. The study included a run-in period with naproxen. Treatments were: naproxen 500 mg on 2 consecutive days (run-in), followed by a 14-day washout period, and then randomization either to BAY 59-7939 15 mg; or to naproxen 500 mg on the first day, and naproxen 500 mg and BAY 59-7939 15 mg on the second day. There was a 14-day washout period between crossovers. BAY 59-7939, naproxen, and the combination were well tolerated. Adverse events (eight in total) were reported by three subjects, and all were mild in intensity; there were no drug-related, treatment-emergent adverse events. BAY 59-7939 significantly inhibited Factor Xa activity by 35%, and prolonged prothrombin time (by 1.4 times baseline [tb]), activated partial thromboplastin time (1.3 tb), and HepTest (1.9 tb), with no influence from naproxen. No interaction was observed with respect to collagen-stimulated platelet aggregation. BAY 59-7939 and naproxen together significantly increased bleeding time compared with BAY 59-7939 alone; however, this difference was small compared with naproxen alone for all but one subject. This indicates that some subjects may be more sensitive to the combined effect of naproxen and BAY 59-7939. However, analysis of patients\u2019 data from clinical trials after major orthopaedic surgery showed similar bleeding risks in patients with and without co-medication with NSAIDs at BAY 59-7939 doses up to 10 mg twice daily. The area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) for BAY 59-7939 both increased by approximately 10% following co-administration of naproxen; however, this small increase in BAY 59-7939 bioavailability was not considered clinically relevant. In conclusion, there is no relevant interaction between BAY 59-7939 and naproxen, although some individuals may be more sensitive to a combination of these drugs. Initial analysis of data from phase II clinical trials of BAY 59-7939 has shown a similar bleeding risk in patients using NSAIDs concomitantly compared with BAY 59-7939 alone. This will be further substantiated in phase III trials.</jats:p>\n               <jats:p>Parameter Naproxen BAY 59-7939 BAY 59-7939 + naproxen aGeometric mean/geometric coefficient of variation; bMedian relative change from baseline; N=11 for all data Bleeding time (tb)a 1.46/0.583 1.20/0.613 2.17/0.576 Platelet aggregationb 0.052 1.02 0.086 AUC (\u03bcg.h/L)a - 1250/28.56 1396/26.30 Cmax (\u03bc g/L)a - 152.9/31.51 165.3/27.69</jats:p>", "DOI": "10.1182/blood.v106.11.1873.1873", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T01:46:08Z", "timestamp": 1570931168000}, "page": "1873-1873", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor."], "prefix": "10.1182", "volume": "106", "author": [{"given": "Dagmar", "family": "Kubitza", "sequence": "first", "affiliation": [{"name": "Institute of Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany"}, {"name": "(Intr. by Frank Misselwitz)"}]}, {"given": "Michael", "family": "Becka", "sequence": "additional", "affiliation": [{"name": "Department of Biometry, Pharmacometry, Bayer HealthCare AG, Wuppertal, Germany"}, {"name": "(Intr. by Frank Misselwitz)"}]}, {"given": "Wolfgang", "family": "Mueck", "sequence": "additional", "affiliation": [{"name": "Institute of Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany"}, {"name": "(Intr. by Frank Misselwitz)"}]}, {"given": "Michael", "family": "Zuehlsdorf", "sequence": "additional", "affiliation": [{"name": "Institute of Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany"}, {"name": "(Intr. by Frank Misselwitz)"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/106/11/1873/137997/Naproxen-Has-No-Relevant-Effect-on-the-Safety", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/106/11/1873/137997/Naproxen-Has-No-Relevant-Effect-on-the-Safety", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T01:46:08Z", "timestamp": 1570931168000}, "score": 27.57446, "issued": {"date-parts": [[2005, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2005, 11, 16]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1182/blood.v106.11.1873.1873", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T06:51:25Z", "timestamp": 1574405485877}, "reference-count": 11, "publisher": "Springer Science and Business Media LLC", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[2010, 2]]}, "DOI": "10.2165/11317590-000000000-00000", "type": "journal-article", "created": {"date-parts": [[2010, 1, 14]], "date-time": "2010-01-14T07:51:48Z", "timestamp": 1263455508000}, "page": "119-129", "source": "Crossref", "is-referenced-by-count": 13, "title": ["Population Pharmacokinetics and Pharmacodynamics of Cinaciguat, a Soluble Guanylate Cyclase Activator, in Patients with Acute Decompensated Heart Failure"], "prefix": "10.1007", "volume": "49", "author": [{"given": "Wolfgang", "family": "Mueck", "sequence": "first", "affiliation": []}, {"given": "Reiner", "family": "Frey", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "R1-3-20100114", "author": "Stasch", "volume": "136", "first-page": "773", "year": "2002", "journal-title": "Br J Pharmacol", "DOI": "10.1038/sj.bjp.0704778", "doi-asserted-by": "crossref"}, {"key": "R2-3-20100114", "author": "Schmidt", "volume": "468", "first-page": "167", "year": "2003", "journal-title": "Eur J Pharmacol", "DOI": "10.1016/S0014-2999(03)01674-1", "doi-asserted-by": "crossref"}, {"key": "R3-3-20100114", "author": "Schmidt", "volume": "279", "first-page": "3025", "year": "2004", "journal-title": "J Biol Chem", "DOI": "10.1074/jbc.M310141200", "doi-asserted-by": "crossref"}, {"key": "R4-3-20100114", "author": "Schmidt", "volume": "513", "first-page": "67", "year": "2005", "journal-title": "Eur J Pharmacol", "DOI": "10.1016/j.ejphar.2005.02.046", "doi-asserted-by": "crossref"}, {"key": "R5-3-20100114", "author": "Stasch", "volume": "116", "first-page": "2552", "year": "2006", "journal-title": "J Clin Invest", "DOI": "10.1172/JCI28371", "doi-asserted-by": "crossref"}, {"key": "R7-3-20100114", "author": "Evgenov", "volume": "5", "first-page": "755", "year": "2006", "journal-title": "Nat Rev Drug Discov", "DOI": "10.1038/nrd2038", "doi-asserted-by": "crossref"}, {"key": "R8-3-20100114", "author": "Frey", "volume": "48", "first-page": "1400", "year": "2008", "journal-title": "J Clin Pharmacol", "DOI": "10.1177/0091270008322906", "doi-asserted-by": "crossref"}, {"key": "R9-3-20100114", "author": "Lapp", "volume": "119", "first-page": "2781", "year": "2009", "journal-title": "Circulation", "DOI": "10.1161/CIRCULATIONAHA.108.800292", "doi-asserted-by": "crossref"}, {"key": "R10-3-20100114", "author": "Holford", "volume": "16", "first-page": "143", "year": "1982", "journal-title": "Pharmacol Ther", "DOI": "10.1016/0163-7258(82)90051-1", "doi-asserted-by": "crossref"}, {"key": "R12-3-20100114", "author": "Cockcroft", "volume": "16", "first-page": "31", "year": "1976", "journal-title": "Nephron", "DOI": "10.1159/000180580", "doi-asserted-by": "crossref"}, {"key": "R13-3-20100114", "author": "Leithe", "volume": "69", "first-page": "57", "year": "1984", "journal-title": "Circulation", "DOI": "10.1161/01.CIR.69.1.57", "doi-asserted-by": "crossref"}], "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2019, 2, 25]], "date-time": "2019-02-25T17:58:32Z", "timestamp": 1551117512000}, "score": 26.970655, "subtitle": [""], "issued": {"date-parts": [[2010, 2]]}, "references-count": 11, "journal-issue": {"issue": "2"}, "URL": "http://dx.doi.org/10.2165/11317590-000000000-00000", "relation": {"cites": []}, "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T05:51:45Z", "timestamp": 1575265905390}, "reference-count": 16, "publisher": "Elsevier BV", "issue": "5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2018, 5, 1]], "date-time": "2018-05-01T00:00:00Z", "timestamp": 1525132800000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "start": {"date-parts": [[2018, 1, 30]], "date-time": "2018-01-30T00:00:00Z", "timestamp": 1517270400000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "europeanneuropsychopharmacology.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Neuropsychopharmacology"], "published-print": {"date-parts": [[2018, 5]]}, "DOI": "10.1016/j.euroneuro.2018.01.003", "type": "journal-article", "created": {"date-parts": [[2018, 3, 19]], "date-time": "2018-03-19T23:28:03Z", "timestamp": 1521502083000}, "page": "643-655", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 3, "title": ["The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers"], "prefix": "10.1016", "volume": "28", "author": [{"given": "Viktoria", "family": "Moschetti", "sequence": "first", "affiliation": []}, {"given": "Maria", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Sand", "sequence": "additional", "affiliation": []}, {"given": "Glen", "family": "Wunderlich", "sequence": "additional", "affiliation": []}, {"given": "Grit", "family": "Andersen", "sequence": "additional", "affiliation": []}, {"given": "Ulrich", "family": "Feifel", "sequence": "additional", "affiliation": []}, {"given": "In-Jin", "family": "Jang", "sequence": "additional", "affiliation": []}, {"given": "Wolfgang", "family": "Timmer", "sequence": "additional", "affiliation": []}, {"given": "Holger", "family": "Rosenbrock", "sequence": "additional", "affiliation": []}, {"given": "Katja", "family": "Boland", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Neuropsychopharmacology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0924977X18300233?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0924977X18300233?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 7, 4]], "date-time": "2018-07-04T01:48:35Z", "timestamp": 1530668915000}, "score": 26.958124, "issued": {"date-parts": [[2018, 5]]}, "references-count": 16, "journal-issue": {"published-print": {"date-parts": [[2018, 5]]}, "issue": "5"}, "alternative-id": ["S0924977X18300233"], "URL": "http://dx.doi.org/10.1016/j.euroneuro.2018.01.003", "ISSN": ["0924-977X"], "issn-type": [{"value": "0924-977X", "type": "print"}], "subject": ["Pharmacology (medical)", "Biological Psychiatry", "Pharmacology", "Neurology", "Psychiatry and Mental health", "Clinical Neurology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers", "name": "articletitle", "label": "Article Title"}, {"value": "European Neuropsychopharmacology", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.euroneuro.2018.01.003", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2018 The Author(s). Published by Elsevier B.V.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T17:57:05Z", "timestamp": 1574445425550}, "reference-count": 30, "publisher": "Wiley", "issue": "5", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1874, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2010, 11]]}, "DOI": "10.1111/j.1365-2125.2010.03753.x", "type": "journal-article", "created": {"date-parts": [[2010, 7, 15]], "date-time": "2010-07-15T19:26:43Z", "timestamp": 1279222003000}, "page": "703-712", "source": "Crossref", "is-referenced-by-count": 239, "title": ["Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor"], "prefix": "10.1111", "volume": "70", "author": [{"given": "Dagmar", "family": "Kubitza", "sequence": "first", "affiliation": []}, {"given": "Michael", "family": "Becka", "sequence": "additional", "affiliation": []}, {"given": "Wolfgang", "family": "Mueck", "sequence": "additional", "affiliation": []}, {"given": "Atef", "family": "Halabi", "sequence": "additional", "affiliation": []}, {"given": "Haidar", "family": "Maatouk", "sequence": "additional", "affiliation": []}, {"given": "Norbert", "family": "Klause", "sequence": "additional", "affiliation": []}, {"given": "Volkmar", "family": "Lufft", "sequence": "additional", "affiliation": []}, {"given": "Dominic D.", "family": "Wand", "sequence": "additional", "affiliation": []}, {"given": "Thomas", "family": "Philipp", "sequence": "additional", "affiliation": []}, {"given": "Heike", "family": "Bruck", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2010, 7, 15]]}, "reference": [{"key": "10.1111/j.1365-2125.2010.03753.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "e85", "DOI": "10.1161/CIRCULATIONAHA.105.171600", "article-title": "American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee", "volume": "113", "author": "Thom", "year": "2006", "journal-title": "Circulation"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "I4", "DOI": "10.1161/01.CIR.0000078468.11849.66", "article-title": "The epidemiology of venous thromboembolism", "volume": "107", "author": "White", "year": "2003", "journal-title": "Circulation"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1007/s11239-006-5572-y", "article-title": "The epidemiology of venous thromboembolism in the community: implications for prevention and management", "volume": "21", "author": "Heit", "year": "2006", "journal-title": "J Thromb Thrombolysis"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "381S", "DOI": "10.1378/chest.08-0656", "article-title": "American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)", "volume": "133", "author": "Geerts", "year": "2008", "journal-title": "Chest"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "546S", "DOI": "10.1378/chest.08-0678", "article-title": "American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)", "volume": "133", "author": "Singer", "year": "2008", "journal-title": "Chest"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1161/01.ATV.0000046238.23903.FC", "article-title": "The dynamics of thrombin formation", "volume": "23", "author": "Mann", "year": "2003", "journal-title": "Arterioscler Thromb Vasc Biol"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "412", "DOI": "10.1016/j.clpt.2005.06.011", "article-title": "Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor", "volume": "78", "author": "Kubitza", "year": "2005", "journal-title": "Clin Pharmacol Ther"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "873", "DOI": "10.1007/s00228-005-0043-5", "article-title": "Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects", "volume": "61", "author": "Kubitza", "year": "2005", "journal-title": "Eur J Clin Pharmacol"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "2374", "DOI": "10.1161/CIRCULATIONAHA.106.642074", "article-title": "ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement", "volume": "114", "author": "Eriksson", "year": "2006", "journal-title": "Circulation"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "2765", "DOI": "10.1056/NEJMoa0800374", "article-title": "RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty", "volume": "358", "author": "Eriksson", "year": "2008", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1016/S0140-6736(08)60880-6", "article-title": "Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial", "volume": "372", "author": "Kakkar", "year": "2008", "journal-title": "Lancet"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "2776", "DOI": "10.1056/NEJMoa076016", "article-title": "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty", "volume": "358", "author": "Lassen", "year": "2008", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "1673", "DOI": "10.1016/S0140-6736(09)60734-0", "article-title": "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial", "volume": "373", "author": "Turpie", "year": "2009", "journal-title": "Lancet"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "180", "DOI": "10.1161/CIRCULATIONAHA.106.668020", "article-title": "ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study", "volume": "116", "author": "Agnelli", "year": "2007", "journal-title": "Circulation"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "2242", "DOI": "10.1182/blood-2008-05-160143", "article-title": "Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study", "volume": "112", "author": "Buller", "year": "2008", "journal-title": "Blood"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB16|cit16", "unstructured": "Bayer Schering Pharma AG Xarelto\u00ae summary of product characteristics http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "891", "DOI": "10.1080/00498250500250493", "article-title": "Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs", "volume": "35", "author": "Weinz", "year": "2005", "journal-title": "Xenobiotica"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "335", "DOI": "10.5414/CPP45335", "article-title": "Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in healthy subjects", "volume": "45", "author": "Mueck", "year": "2007", "journal-title": "Int J Clin Pharmacol Ther"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "11", "DOI": "10.1016/S1073-4449(00)70002-1", "article-title": "Biology of renal aging in humans", "volume": "7", "author": "Clark", "year": "2000", "journal-title": "Adv Ren Replace Ther"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "2479", "DOI": "10.1111/j.1538-7836.2005.01602.x", "article-title": "BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study", "volume": "3", "author": "Turpie", "year": "2005", "journal-title": "J Thromb Haemost"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "121", "DOI": "10.1111/j.1538-7836.2005.01657.x", "article-title": "ODIXa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement", "volume": "4", "author": "Eriksson", "year": "2006", "journal-title": "J Thromb Haemost"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "203", "DOI": "10.2165/00003088-200847030-00006", "article-title": "Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery", "volume": "47", "author": "Mueck", "year": "2008", "journal-title": "Clin Pharmacokinet"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "105", "DOI": "10.2215/CJN.01810407", "article-title": "Major bleeding in hemodialysis patients", "volume": "3", "author": "Holden", "year": "2008", "journal-title": "Clin J Am Soc Nephrol"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "771", "DOI": "10.1160/TH07-02-0132", "article-title": "Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry", "volume": "98", "author": "Falga", "year": "2007", "journal-title": "Thromb Haemost"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "579", "DOI": "10.1055/s-2004-835678", "article-title": "Platelet dysfunction in renal failure", "volume": "30", "author": "Boccardo", "year": "2004", "journal-title": "Semin Thromb Hemost"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB26|cit26", "unstructured": "Sanofi-aventis Lovenox (enoxaparin sodium injection) for subcutaneous and intravenous use. Prescribing information http://products.sanofi-aventis.us/lovenox/lovenox.pdf"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB27|cit27", "unstructured": "Glaxo Group Ltd Arixtra 2.5\u2003mg/0.5\u2003ml solution for injection, pre-filled syringe. Summary of product characteristics http://www.medicines.org.uk/emc/medicine/15123"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "291", "DOI": "10.2165/00129784-200505050-00002", "article-title": "Anticoagulant use in patients with chronic renal impairment", "volume": "5", "author": "Grand'Maison", "year": "2005", "journal-title": "Am J Cardiovasc Drugs"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.2165/0003088-200948010-00001", "article-title": "Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development", "volume": "48", "author": "Eriksson", "year": "2009", "journal-title": "Clin Pharmacokinet"}, {"key": "10.1111/j.1365-2125.2010.03753.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "453", "DOI": "10.1160/TH07-12-0714", "article-title": "Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement", "volume": "100", "author": "Mueck", "year": "2008", "journal-title": "Thromb Haemost"}], "container-title": ["British Journal of Clinical Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2125.2010.03753.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 2]], "date-time": "2019-03-02T05:07:12Z", "timestamp": 1551503232000}, "score": 26.881926, "subtitle": ["Rivaroxaban pharmacokinetics, pharmacodynamics and safety in renal impairment"], "issued": {"date-parts": [[2010, 7, 15]]}, "references-count": 30, "journal-issue": {"published-print": {"date-parts": [[2010, 11]]}, "issue": "5"}, "URL": "http://dx.doi.org/10.1111/j.1365-2125.2010.03753.x", "relation": {"cites": []}, "ISSN": ["0306-5251"], "issn-type": [{"value": "0306-5251", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T05:11:43Z", "timestamp": 1574831503725}, "reference-count": 0, "publisher": "Oxford University Press", "isbn-type": [{"value": "9780198729471", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016, 3]]}, "DOI": "10.1093/med/9780198729471.003.0003", "type": "book-chapter", "created": {"date-parts": [[2016, 8, 22]], "date-time": "2016-08-22T12:58:44Z", "timestamp": 1471870724000}, "page": "59-86", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Adverse effects and antipsychotic long-acting injections"], "prefix": "10.1093", "author": [{"given": "Peter", "family": "Haddad", "sequence": "first", "affiliation": []}, {"given": "W. Wolfgang", "family": "Fleischhacker", "sequence": "additional", "affiliation": []}], "member": "286", "container-title": ["Antipsychotic Long-acting Injections"], "deposited": {"date-parts": [[2017, 11, 7]], "date-time": "2017-11-07T13:57:50Z", "timestamp": 1510063070000}, "score": 26.777256, "issued": {"date-parts": [[2016, 3]]}, "ISBN": ["9780198729471"], "references-count": 0, "URL": "http://dx.doi.org/10.1093/med/9780198729471.003.0003"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T19:35:45Z", "timestamp": 1575228945588}, "reference-count": 0, "publisher": "Oxford University Press", "isbn-type": [{"value": "9780199586042", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2010, 10]]}, "DOI": "10.1093/med/9780199586042.003.0003", "type": "book-chapter", "created": {"date-parts": [[2013, 5, 30]], "date-time": "2013-05-30T09:53:24Z", "timestamp": 1369907604000}, "page": "47-70", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Adverse effects and antipsychotic long-acting injections*"], "prefix": "10.1093", "author": [{"given": "Peter", "family": "Haddad", "sequence": "first", "affiliation": []}, {"given": "W. Wolfgang", "family": "Fleischhacker", "sequence": "additional", "affiliation": []}], "member": "286", "container-title": ["Antipsychotic long-acting injections"], "deposited": {"date-parts": [[2017, 11, 7]], "date-time": "2017-11-07T14:58:04Z", "timestamp": 1510066684000}, "score": 26.777256, "issued": {"date-parts": [[2010, 10]]}, "ISBN": ["9780199586042"], "references-count": 0, "URL": "http://dx.doi.org/10.1093/med/9780199586042.003.0003"}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}